


PCT/US 98/19600

B4



REC'D 29 OCT 1998

WIPO

PCT

EA

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

October 23, 1998

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/059,353

FILING DATE: September 19, 1997

PCT APPLICATION NUMBER: PCT/US98/19600

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*L. Edelen*

L. EDELEN  
Certifying Officer



266760-ES65009

A/PRV

Practitioner's Docket No. 22722/OMP.PRV

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rikihisa, et al.

For: OUTER MEMBRANE PROTEIN OF EHRLICHIA CANIS AND EHRLICHIA  
CHAFFENIS  
Box Provisional Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

COVER SHEET FOR FILING PROVISIONAL APPLICATION  
(37 C.F.R. § 1.51(2)(i))

**WARNING:** "A provisional application must also include a cover sheet identifying the application as a provisional application. Otherwise, the application will be treated as an application filed under § 1.53(b)(1)." 37 C.F.R. § 1.53(b)(2)(i).

**NOTE:** "A complete provisional application does not require claims since no examination on the merits will be given to a provisional application. However, provisional applications may be filed with one or more claims as part of the application. Nevertheless, no additional claim fee or multiple dependent claims fee will be required in a provisional application." Notice of December 5, 1994, 59 FR 63951, at 63953.  
"Any claim filed with a provisional application will, of course, be considered part of the original provisional application disclosure." Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,209.

**NOTE:** "A provisional application shall not be entitled to the right of priority under § 1.55 or 35 U.S.C. 119 or 365(a) or to the benefit of an earlier filing date under § 1.78 or 35 U.S.C. 120, 121 or 365(c) of any other application." 37 C.F.R. § 1.53(b)(2)(ii).

**NOTE:** "No information disclosure statement may be filed in a provisional application." 37 C.F.R. § 1.51(2)(b).  
"Any information disclosure statements filed in a provisional application would either be returned or disposed of at the convenience of the Office." Notice of December 5, 1994, 59 FR 63591, at 63594.

**NOTE:** "No amendment other than to make the provisional application comply with all applicable regulations, may be made to the provisional application after the filing date of the provisional application." 37 C.F.R. § 1.53(b)(2).

CERTIFICATION UNDER 37 C.F.R. 1.10\*  
(Express Mail label number is mandatory.)  
(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on September 17, 1997 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, Mailing Label Number 94238368245US addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Pamela A. Docherty  
(type or print name of person mailing paper)

Pamela A. Docherty  
Signature of person mailing paper

**WARNING:** Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

WARNING: A provisional application may be abandoned by operation of 35 U.S.C. 111(b)(5) on a Saturday, Sunday, or Federal holiday within the District of Columbia, in which case, a nonprovisional application claiming benefit of the provisional application under 35 U.S.C. 119(e) must be filed no later than the preceding day that is not a Saturday, Sunday, or Federal holiday within the District of Columbia. Notice of April 14, 1995, 60 Fed. Reg. 20,195 at 20,202.

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 C.F.R. 1.53(b)(2).

1. The following comprises the information required by 37 C.F.R. § 1.51(a)(2)(i)(A):
2. The name(s) of the inventor(s) is/are (37 C.F.R. § 1.51(a)(2)(i)(B)):

NOTE: While the name or names of the inventors are required in order to accord a provisional application a filing date, a provisional application is not required to be signed by the inventor or the assignee. No oath or declaration is required. Presumably, most provisional applications will be filed by a registered practitioner without a power of attorney being filed. Notice of December 5, 1994, 59 FR 63591, at 63594.

NOTE: "The naming of inventors for obtaining a filing date for a provisional application is the same as for other applications. A provisional application filed with the inventors identified as 'Jones et al.' will not be accorded a filing date earlier than the date upon which the name of each inventor is supplied unless a petition with the fee set forth in § 1.17(f) is filed which sets forth the reasons the delay in supplying the names should be excused. Administrative oversight is an acceptable reason. It should be noted that for a 35 U.S.C. 111(a) application to be entitled to claim the benefit of the filing date of a provisional application the 35 U.S.C. 111(a) application must have at least one inventor in common with the provisional application." Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,209.

The term "invention" is typically used to refer to subject matter which applicant is claiming in his/her application. Because claims are not required in a provisional application, it would not be appropriate to reference joint inventors as those who have made a contribution to the "invention" disclosed in the provisional application. If the "invention" has not been determined in the provisional application because no claims have been presented, then the name(s) of those person(s) who have made a contribution to the subject matter disclosed in the provisional application should be submitted. Section 1.45(c) states that "if multiple inventors are named in a provisional application, each named inventor must have made a contribution, individually or jointly, to the subject matter disclosed in the provisional application." All that § 1.45(c) requires is that if someone is named as an inventor, that person must have made a contribution to the subject matter disclosed in the provisional application. When applicant has determined what the invention is by the filing of the 35 U.S.C. 111(a) application, that is the time when the correct inventors must be named. The 35 U.S.C. 111(a) application must have an inventor in common with the provisional application in order for the 35 U.S.C. 111(a) application to be entitled to claim the benefit of the provisional application under 35 U.S.C. 119(e). Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,208.

"If all the names of the actual inventor or inventors are not supplied when the specification and any required drawings are filed, the provisional application will not be given a filing date earlier than the date upon which the names are supplied unless a petition, with the fee set forth in § 1.17(q), is filed, which sets forth that the reasons for the delay in supplying the names should be excused." 37 C.F.R. § 1.53(b)(2).

1.	<u>Yasuko</u>	<u>Rikihisa</u>
	GIVEN NAME	FAMILY (OR LAST) NAME
	MIDDLE INITIAL OR NAME	
2.	<u>Noris</u>	<u>Ohashi</u>
	GIVEN NAME	FAMILY (OR LAST) NAME
	MIDDLE INITIAL OR NAME	
3.		
	GIVEN NAME	FAMILY (OR LAST) NAME
	MIDDLE INITIAL OR NAME	

2025-05-20 14:00:00

3. Address(es) of the inventor(s), as numbered above (37 C.F.R. § 1.51(a)(2)(i)(C)):

1. 1120 Woodman Drive, Worthington, Ohio 43210

2. 1210 Chambers Road, Columbus, Ohio 43212

3. \_\_\_\_\_

4. The title of the invention is (37 C.F.R. § 1.51(a)(2)(i)(D)):

Outer Membrane Protein of Ehrlichia Canis and Ehrlichia  
Chaffeensis

5. The name, registration, and telephone number of the practitioner (if applicable) is (37 C.F.R. § 1.51(a)(2)(i)(E)):

Name of practitioner: Pamela A. Docherty

Reg. No. 40,591 Tel. (216) 622-8416

(complete the following, if applicable)

☐ A power of attorney accompanies this cover sheet.

6. The docket number used to identify this application is (37 C.F.R. § 1.51(a)(2)(i)(F)):

Docket No.: 22727/OMP.PRV

7. The correspondence address for this application is (37 C.F.R. § 1.51(a)(2)(i)(G)):

CALFEE, HALTER & CRISWOLD LLP, 1400 McDonald Investment Center,  
800 Superior Avenue, Cleveland, Ohio 44114

8. Statement as to whether invention was made by an agency of the U.S. Government or under contract with an agency of the U.S. Government.  
(37 C.F.R. § 1.51(a)(2)(i)(H))

This invention was made by an agency of the United States Government, or under contract with an agency of the United States Government.

☒ No.

☐ Yes.

The name of the U.S. Government agency and the Government contract number are: \_\_\_\_\_

9. Identification of documents accompanying this cover sheet:

A. Documents required by 37 C.F.R. §§ 1.51(a)(2)(ii)-(iii):

Specification:

No. of pages 71

Drawings: within the specification

No. of sheets 27

B. Additional documents:

☐ Claims:

No. of claims         

Note: A complete provisional application does not require claims. 37 C.F.R. § 1.51(a)(2).

☐ Power of attorney

☐ Small entity statement

☐ Assignment

☐ Other

NOTE: Provisional applications may be filed in a language other than English as set forth in existing § 1.52(d). However, an English language translation is necessary for security screening purposes. Therefore, the PTO will require the English language translation and payment of the fee mandated in § 1.52(d) in the provisional application. Failure to timely submit the translation in response to a PTO requirement will result in the abandonment of the provisional application. If a 35 U.S.C. 111(a) application is filed without providing the English language translation in the provisional application, the English language translation will be required to be supplied in every 34 U.S.C. 111(a) application claiming priority of the non-English language provisional application. Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,209.

10. Fee

The filing fee for this provisional application, as set in 37 C.F.R. § 1.16(k), is \$150.00, for other than a small entity, and \$75.00, for a small entity.

☐ Applicant is a small entity.

NOTE: "A verified statement in compliance with existing § 1.27 is required to be filed in each provisional application in which it is desired to pay reduced fees." Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,197.

11. Small entity statement

☐ The verified statement(s) that this is a filing by a small entity under 37 C.F.R. §§ 1.9 and 1.27 is(are) attached.

12. Fee payment being made at this time

☒ Not enclosed

☒ No filing fee is to be paid at this time. (This and the surcharge required by 37 C.F.R. § 1.16(l) can be paid subsequently).

☐ Enclosed

Total fee enclosed \$

## 13. Method of fee payment

- ☐ Check in the amount of \$ \_\_\_\_\_
- ☐ Charge Account No. \_\_\_\_\_, in the amount of \$ \_\_\_\_\_
- A duplicate of this Cover Sheet is attached.

Please charge Account No. \_\_\_\_\_ for any fee deficiency.

Date: \_\_\_\_\_

Tel.: (     )

Signature of submitter

OR

Pamela A. Docherty  
Signature of practitioner

Pamela A. Docherty

(type or print name of practitioner)  
Calfee, Halter & Griswold LLP  
1400 McDonald Investment Center

P.O. Address  
800 Superior Avenue  
Cleveland, Ohio 44114

Date: September 19, 1997

Reg. No.: 40,591

Tel.: (216) 622-8416

Customer No.:

6059353-091997

"Express Mail" Mailing Label Number EM238 368 245US

Date of Deposit September 19, 1997

22727/OMP.PR.V

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D. C. 20231.

## ABSTRACT

Canine ehrlichiosis consists of an acute and a chronic phase. The acute phase is characterized by fever, serous nasal and ocular discharges, anorexia, depression, and loss of weight. The chronic phase is characterized by thrombocytopenia, epistaxis, hematuria, blood in feces in addition to more severe clinical signs of the acute disease. The disease occurs throughout the world and is especially prevalent in Southeast Asia. Canine ehrlichiosis is found throughout the United States. If treated early during the course of the disease, dogs respond well to doxycycline. However, chronically infected dogs do not respond well to the antibiotic. Therefore, early diagnosis is very important for treating canine ehrlichiosis. The indirect fluorescent antibody (IFA) test that uses the etiologic agent, Ehrlichia canis, as antigen, has been the most frequently used for laboratory diagnosis of canine ehrlichiosis. The IFA test has, however, serious limitations: 1) the IFA test is subjective and produces false positive or negative results by an inadequately trained examiner; 2) the IFA test requires a special equipment to perform the test. A simpler, more rapid, and objective serodiagnosis is desirable for canine ehrlichiosis. We report here that for the first time we cloned and expressed 30 kDa, the major antigenic protein of E. canis. Using the recombinant E. canis 30 kDa protein as antigen we developed sensitive and simple dot blot assay which detects E. canis infection in dogs. Since this antigen is the major surface antigen of E. canis we predict that this recombinant protein is also useful for vaccine preparation against canine ehrlichiosis.

## INTRODUCTION

Canine ehrlichiosis consists of an acute and a chronic phase. All susceptible dogs exhibit the acute signs, but hemorrhagic signs that characterize the severe chronic form are less predictable and tend to occur in certain breeds, especially German shepherds, 2 to 4 months after the earlier febrile episode. Within 7 to 11 days following inoculation with infective blood, susceptible dogs develop signs of acute disease consisting of fever, serous nasal and ocular discharges, anorexia, depression, and loss of weight. Hematologic findings in the acute phase include thrombocytopenia and nonregenerative anemia (12). Leukocyte counts are variable and sometimes increase during the first 2 to 3 weeks of infection. Leukopenia, if it occurs, probably relates to increased sequestration or destruction of circulating leukocytes. Increases in serum ALT occur, especially in the acute phase of the disease. Dogs that reach the severe pancytopenic stage of chronic infection have a poor prognosis despite therapy. Death is usually caused by complications of secondary infection or hemorrhage.

Canine ehrlichiosis is transmitted by the brown dog tick, Rhipicephalus sanguineus, transstadially but not transovarially, leading to the conclusion that canids, not ticks, are reservoirs. Vertebrate hosts for E. canis appear to be restricted to members of the family Canidae. The jackal, coyote, and fox have been infected with E. canis experimentally. Donatien and Lestoquard reported experimental infection of a monkey, Macacus inuus, but their findings have not been confirmed.

The indirect fluorescence antibody (IFA) test is the clinical laboratory test currently most frequently used for canine ehrlichiosis. My laboratory has developed enzyme-linked

immunosorbent assay (ELISA) and Western immunoblot procedure and a single step and a nested PCR for canine ehrlichiosis. All of these methods are cumbersome and require special equipment to perform. IgM and IgG IFA and ELISA did not vary substantially in detecting early stages of infection. Western blot procedure provides information of antibody reactions to individual *E. canis* antigenic proteins. By western blot analysis of both experimentally and naturally infected dogs, the 30 kDa antigen of *E. canis* was identified as the major antigen reacted with all infected dogs. My laboratory cloned and expressed the major antigen of *E. canis* 30 kDa major outer membrane protein.

The dot-immunoblot assay has been developed for diagnosis of rickettsial organisms. The assay is relatively simple and does not require special equipment as long as membrane strips coated with a high quality antigen are available. Advantage of the recombinant *E. canis* 30kDa major antigen over the purified *E. canis* antigen is its purity and consistency in quality. Therefore, we evaluated our recombinant *E. canis* 30kDa antigens by western immunoblot and by dot blot assay.

## DATA

Figure 11 demonstrates that we obtained the recombinant clone which expresses a large quantity of *E. canis* major antigen 30 kDa (Fig. 11A). The size of the recombinant protein is slightly smaller than the native protein due to our technical manipulation for its efficient expression. Fig. 1B compared uninfected dog macrophage DH82 cells (which we used as negative control antigen in Fig. 2), purified whole *E. canis*, sonication-insoluble recombinant *E. canis* 30 kDa protein (this means partially purified--this is >90% pure), and affinity chromatography-purified recombinant *E. canis* 30 kDa protein (100% pure). The amount of 30 kDa protein expressed in recombinant *E. coli* is much greater than the amount naturally present in *E. canis*. This proves that we obtained recombinant *E. canis* 30 kDa antigenic protein and established the method to purify it.

Figure 12 demonstrates that this recombinant *E. canis* 30 kDa antigenic protein is highly antigenic and has much stronger antigen than native *E. canis* 30 kDa protein. My LABORATORY has over 2,000 dog sera tested by indirect fluorescent antibody (IFA) test using *E. canis* as antigen. Representative 7 dog sera with different IFA titer was used for this study. Dog macrophage DH82 cells and *E. coli* were used as control antigen. The purified *E. canis* and the recombinant *E. canis* 30 kDa antigenic protein were compared for their reactivity with dog sera of different IFA titers by Western immunoblot analysis. As seen clearly in Fig. 2 IFA negative dog sera has no reaction to any antigens used. Anti-*E. canis* sera of greater than 1:20 IFA titers, diluted at 1: 1,000 all reacted strongly with native and recombinant 30 kDa antigens. This is the major antigen recognized by the infected dogs. The reactivity of recombinant antigen is much stronger than that of native *E. canis* antigen. The Western blot results are summarized in Table 1.

Figure 13 shows that using dog sera of different IFA titers, we compared the effect of preabsorption of dog sera with *E. coli*, since most dogs have an antibody against *E. coli*. As seen in Fig. 3 our dot blot assay using semi-purified recombinant 30 kDa antigen can detect all IFA



positive sera including that of 1:20 IFA titer. The negative dog sera was negative. Preabsorption of dog sera with *E. coli* is not required, since there is no nonspecific reaction of dog sera to the recombinant antigen preparation. There was also no difference in sensitivity and specificity between chromatography purified and semi-purified recombinant antigens in the dot blot assay. This proves that our recombinant *E. canis* antigen is useful for serodiagnosis of canine ehrlichiosis.

Finally since recombinant 30 kDa antigen is the major surface antigen of *E. canis*, I predict this is effective as the component of canine ehrlichiosis vaccine.

## REFERENCES

1. Dawson, J.E., Y. Rikihisa, S. Ewing and D.B. Fishbein (1991) Serologic diagnosis of human ehrlichiosis using two *Ehrlichia canis* isolates. *J. Infect. Dis.* **163**, 564-567.
2. Rikihisa, Y. (1991) Cross-reacting antigens between *Neorickettsia helminthoeca* and *Ehrlichia ssp.* shown by immunofluorescence and Western immunoblotting. *J. Clin. Microbiol.* **29**, 2024-2029.
3. Rikihisa, Y. (1991) The tribe *Ehrlichieae* and ehrlichial diseases. *Clin. Microbiol. Rev.* **4**:286-308.
4. Rikihisa, Y., S.A. Ewing, J.C. Fox, A.G. Siregar, F.H. Pasaribu, and M.B. Malole. (1992) Enzyme-linked immunosorbent assay and western immunoblot analysis of *E. canis* and canine granulocytic *Ehrlichia*. *J. Clin. Microbiol.* **30**, 143-148.
5. Yamamoto, S., S. Miyaji, Y. Ashida, Y. Nishimura, H. Niizeki, and Y. Rikihisa. (1994) Serosurvey of anti-*Ehrlichia canis* antibody in dogs. *J. Japanese Small Animal Veterinary Med. Assoc.* **47**, 765-767. (In Japanese).
6. Rikihisa, Y., S. Yamamoto, I. Kwak, Z. Iqbal, J. Mott, and G. Kociba. (1994) Plasma C reactive protein and ocl-acidglyco protein concentrations in dogs infected with *Ehrlichia canis*. *J. Clin. Microbiol.* **32**, 912-917.
7. Rikihisa, Y., S.A. Ewing, and J.C. Fox. (1994) Western immunoblot analysis of *Ehrlichia chaffeensis*, *E. canis*, or *E. ewingii* infection of dogs and human. *J. Clin. Microbiol.* **32**, 2107-2112.
8. Iqbal, Z., and Y. Rikihisa. (1994) Reisolation of *Ehrlichia canis* from blood and tissues of dogs after treatment with doxycycline. *J. Clin. Microbiol.* **32**, 1644-1649.
9. Iqbal, Z., W. Chaichanasiriwithaya, and Y. Rikihisa. (1994) Comparison of PCR and Western immunoblot analysis in early diagnosis of canine ehrlichiosis. *J. Clin. Microbiol.* **32**, 1658-1662.
10. Iqbal, Z. and Y. Rikihisa. (1994) Application of polymerase chain reaction for detection of *Ehrlichia canis* in tissues of dogs. *Vet. Microbiol.* **42**, 281-287.
11. Rikihisa, Y. (1995) Ehrlichial Diseases. In *Zoonotic Diseases*. *Clin. Microbiol.* **22**, 413-419 (In Japanese).
12. Perez, M., Y. Rikihisa, and B. Wen. (1996) Antigenic and genetic characterization of an *Ehrlichia canis*-like agent isolated from a human in Venezuela. *J. Clin. Microbiol.* **34**:2133-2139.

13. Wen, B., Y. Rikihisa, N. Zhi, R. Greene, and R. Bartsch. (1997) Nested polymerase chain reaction for detection of *Ehrlichia canis* infection in dogs. J. Clin. Microbiol. 35: 1852-1855.
14. Rikihisa, Y. (1990) Ultrastructure of rickettsiae with special emphasis on ehrlichia. In: Ehrlichiosis: A vectorborne Disease of Animals and Humans. In Current Topics in Veterinary Medicine and Animal Sciences, 54, P. 22-31. Ed. by J.C. Williams and I. Kakoma, Kluwer Publishing Co., Norwell, MA.  
Rikihisa, Y. (1996) Ehrlichiae (Plenary Session). In: Proceedings of the 5th International Symposium on Rickettsiae and Rickettsial Diseases (Bratislava, Slovak Republic). Slovak Academy of Sciences, Bratislava, Slovak Republic: International Society of Rickettsiae and Rickettsial Diseases, pp 272-286.

2661607 55065009

Table 1. Reactivities of purified *E. canis* and the recombinant (r) P30 by western blot analysis with clinical dog sera.

Numbers of clinical dog sera	IFA titers	Antigens			
		<i>E. coli</i> host (1) <sup>a)</sup>	DH82 cells	Purified <i>E. canis</i>	rP30 of <i>E. canis</i> (1) <sup>b)</sup>
1	< 1:20	-	-	-	-
2	1:20	-	-	+	+
3	1:40	-	-	+	++
4	1:80	-	-	++	+++
5	1:2,560	-	-	+++	++++
6	1:5,120	-	-	+++	++++
7	1:10,240	-	-	++++	++++

<sup>a)</sup> Sonication-insoluble fraction (1) of *E. coli* host.

<sup>b)</sup> Sonication-insoluble fraction (1) of the recombinant clone (partially purified rP30).

2005053.09197

## ABSTRACT

Five major proteins in 23- to 29-kDa range were identified in an outer membrane fraction prepared from *Ehrlichia chaffeensis*, human ehrlichiosis agent. The NH<sub>2</sub>-terminal amino acid sequence of an immunodominant 28-kDa outer membrane protein (OMP)-1, one of the major OMPs, chemically determined was homologous to that of *Cowdria ruminantium* 32-kDa major antigen protein (MAP)-1. The DNA fragment including the 28-kDa outer membrane protein gene (*omp*)-1 amplified by polymerase chain reaction (PCR) was cloned, sequenced, and expressed. The NH<sub>2</sub>-terminal amino acid sequence of *E. chaffeensis* 23-kDa OMP was found to be similar to a part of the predicted amino acid sequence of *omp*-1. The sequences of 25- and 27-kDa OMPs at the NH<sub>2</sub> termini were homologous. Rabbit and mouse anti-recombinant-OMP-1 antibodies cross-reacted strongly with 25-kDa, 28-kDa (native OMP-1), and 29-kDa OMPs of *E. chaffeensis*. These findings suggest that *E. chaffeensis* in a tissue culture coexpresses several homologous proteins in the 23- to 29-kDa range that have common antigenic epitopes and homologous amino acid sequences, i.e., that these proteins are members of a multi-sized protein antigen family. In an experiment of *E. chaffeensis*-challenge, immunization of recombinant OMP-1 protected mice from the ehrlichial infection. The result suggests that 28-kDa OMP-1 is a candidate for development of vaccine and diagnostic antigen.

*Ehrlichia chaffeensis*, which causes human ehrlichiosis, is an obligatory intracellular bacterium of monocytes and macrophages and belongs to the family *Rickettsiaceae*. Human ehrlichiosis is a newly recognized and emerging rickettsial disease in the United States. The first case was reported in 1987 as a human infection with *Ehrlichia canis*, the causative agent of canine ehrlichiosis, since the patient serum strongly reacted with *E. canis* antigen by indirect fluorescent antibody test (1). However, a new but similar organism, *E. chaffeensis*, was isolated in 1990 at the Centers for Disease Control (CDC), Atlanta, Ga., from a patient from Fort Chaffee, Ark. (2). Since 1987, over 400 cases of human ehrlichiosis detected primarily by serological means have been reported in 30 states (2-4).

So far, few molecular-level studies of the pathogenesis and intracellular parasitism of *E. chaffeensis* have been carried out. This lack is probably due to the difficulty of obtaining a sufficient quantity of viable *E. chaffeensis* in its pure form, since this organism grows slowly in monocyte cell lines and is very fragile. Moreover, it is impossible to apply to obligate intracellular bacteria such as ehrlichiae the gene manipulation techniques generally used with facultative intracellular or extracellular bacteria. Hence, our initial effort was concentrated on identifying the ehrlichial major outer membrane proteins, cloning and expressing their genes, and analyzing the functions of these proteins by using the gene products.

Recently, several proteins, including the heat shock protein (HSP) 60 homolog of *E. chaffeensis*, were identified by Western immunoblot analysis as major antigens in infected human and experimentally inoculated dogs (5-8). Among these antigens, - 30-kDa protein antigens are predominant in both *E. chaffeensis* and *E. canis* and are antigenically cross-reactive between these two *Ehrlichia* spp. (6). However, the nature and localization of these protein antigens and their roles in host immunity are unknown. We reported here the identification of five 23- to 29-kDa major proteins in the outer membrane fraction of *E. chaffeensis*, and the cloning, sequencing, and expression of a 28-kDa protein gene, one of major outer membrane proteins (OMP). Immunization of mice with recombinant 28-kDa protein protected mice from *E.*

*chaffeensis* infection. Surprisingly, these five major proteins were found to belong to a multi-sized protein antigen family whose members have antigenic epitopes and amino acid sequences in common.

## MATERIALS AND METHODS

**Organisms and Purification.** *E. chaffeensis* and *E. canis* cultivated in DH82 dog macrophage cell line (6), were purified by Percoll density gradient centrifugation as described elsewhere (9) but with some modifications. Heavily infected cells (approximately  $6 \times 10^5$ ) were harvested and centrifuged at 800 x g. The pellet was suspended in SPK buffer (0.2 M sucrose and 0.05 M potassium phosphate buffer, pH 7.4) and homogenized on ice with 30 strokes by using a Dounce homogenizer. DNase I, RNase A (Sigma, St. Louis, Mo.), and  $MgCl_2$  (final concentrations of 50  $\mu$ g/ml, 10  $\mu$ g/ml, and 2 mM, respectively) were then added to the homogenate and incubated for 10 min on ice. The homogenate was centrifuged at 400 x g three times for 10 min per time. The nuclease reaction in the supernatant was terminated by adding EDTA (final concentration, 5 mM). The organisms in the supernatant were mixed with Percoll (Sigma) (final Percoll concentration, 32 to 35 %) and centrifuged at 61,900 x g for 30 min. The lower layer was harvested, mixed with SPK buffer, and centrifuged at 11,670 x g for 10 min. The pellet was resuspended in SPK buffer and centrifuged twice to remove Percoll. The protein content of purified ehrlichiae was determined by the Coomassie blue dye-binding assay (Bio-Rad Laboratories, Richmond, CA.) as described (10).

**Preparation of Ehrlichial Outer Membrane.** The procedure for *Orientia tsutsugamushi* (11) was followed with modifications. Purified organisms (100  $\mu$ g of each) were suspended with 10 mM sodium phosphate buffer containing 0.1% Sarkosyl (Sigma), 50  $\mu$ g each of DNase I and RNase A, and 5 mM  $MgCl_2$ . After incubation at 37°C for 30 min and termination of reaction of these nucleases by the addition of EDTA (final concentration, 15 mM), proteins in the soluble supernatant and the insoluble precipitate, separated by centrifugation at 10,000 x g for 1 h, were analyzed by SDS-PAGE as described elsewhere (12). Prestained protein molecular size markers were purchased from GIBCO-BRL (Grand Island, NY) and Bio-Rad.

**Electron Microscopy.** Transmission electron microscopy was performed by a procedure described elsewhere (13). Ultrathin sections (60 nm) were stained with uranyl acetate and lead citrate and observed with a Philips 300 electron microscope at 60 kV.

**NH<sub>2</sub>-Terminal Amino Acid Sequence Analysis.** Proteins of the Sarkosyl-insoluble precipitate from 400  $\mu$ g of whole organisms were separated by a reversed-discontinuous SDS-PAGE (2.5-cm-long 17% gel on top of 11-cm-long 12% gel) and were electrophoretically transferred (at 300 mA for 2 h using a Bio-Rad transblot cell) to a ProBlot™ membrane (Applied Biosystems, Foster City, CA) in 10 mM 3-[cyclohexylaminol-1-propanesulfonic acid (CAPS) (Sigma) and 10% methanol (pH 11). After the proteins on the membrane were stained with 0.1% amido black for 1 min, the bands were cut and individually analyzed with an Applied Biosystems protein sequencer (model 470). A homology search was carried out with data bases of the

GenBank, Swiss Plot, PDB and PIR by using the software basic local alignment search tool (14) in the BLAST network service (the National Center for Biotechnology Information, Bethesda, MD).

**Cloning and Sequencing of PCR-Amplified 28-kDa outer membrane protein gene (*omp*)-1.** Genomic DNA of *E. chaffeensis* was isolated from purified ehrlichiae as described elsewhere (15). Synthetic oligonucleotides containing 5'-terminal sequences for *EcoRI*, *BamHI*, and *NotI* restriction endonucleases were prepared by Bioserve (Laurel, MD). The 5' oligonucleotide (f28pl primer) included the DNA sequence coding for the NH<sub>2</sub>-terminal region of *E. chaffeensis* 28-kDa outer membrane protein (OMP)-1 (amino acid positions 6 to 12), chemically determined, and for the *EcoRI* and *BamHI* restriction endonuclease sites [5'-CG GGA TCC GAA TTC GG(ATGC) AT(ATC) AA(TC)GG(ATGC)AA(TC)TT(TC)TA -3.]. The 3' oligonucleotide (r28pl primer) included the DNA sequence coding for the COOH-terminal region conserved between *Cowdria ruminantium* MAP-1 and *Anaplasma marginate* major surface protein (MSP)-4 with the addition of a *NotI* restriction endonuclease site [5'- AGC GGC CGC TTA (AG)AA (TC)A(CG) (AG)AA (CT)CT T(CG)C TCC -3'1. PCR amplification was carried out with a Perkin-Elmer Cetus DNA Thermal Cycler (model 480) by the standard procedure. The 0.8-kb amplified product of almost-full-length *omp-1* was cloned in the pCR<sup>TM</sup>II vector of a TA cloning kit as described by the manufacturer (Invitrogen Co., San Diego, CA). Both DNA strands of a DNA insert of five recombinant clones were sequenced by a dideoxy termination method with an Applied Biosystems 373A DNA sequencer. One clone was designated pCRIIOMP-1. DNA sequences were analyzed with the DNASIS program (Hitachi Software Engineering Co., Ltd., Yokohama, Japan).

**Overexpression of OMP-1.** The DNA fragment of *omp-1* purified from *EcoRI*- and *NotI*-digested pCRIIOMP-1 after agarose gel electrophoresis was ligated into dephosphorylated, *EcoRI*- and *NotI*-digested pET29a (Novagen, Inc., Madison, WI). *Escherichia coli* NovaBlue (Novagen, Inc.) was transformed with recombinant pET29a. A plasmid preparation of pET29a with *omp-1* from transformed NovaBlue was then used to transform *E. coli* BL21(DE3)pLysS, which has a very low transforming capacity. The induction of the recombinant protein was performed by a procedure described elsewhere (16). A clone, *omp-1*-pET29a-BL21(DE3)pLysS host, was designated as pET29aOMP-1.

**Sera and Western Immunoblot Analysis.** Convalescent-phase serum from a patient with clinical signs of human ehrlichiosis was provided by the CDC, Atlanta, Ga. (6). For preparation of rabbit anti-recombinant OMP-1 serum, the area of the expressed protein band after SDS-PAGE of pET29aOMP-1 cells was excised without Coomassie blue staining. The gel was minced in phosphate-buffered saline, pH 7.4, and mixed with an equal volume of Freund's incomplete adjuvant (Sigma), and the mixture was subcutaneously injected into a rabbit four times at 2-week intervals (1 mg of protein each time). Anti-*E. chaffeensis* antibody titer was determined by indirect immunofluorescence assay (IFA) as described elsewhere (17). The IFA titers of the patient serum and the rabbit anti-recombinant OMP-1 serum against *E. chaffeensis* antigen were 1:2,560 and 1:1,280, respectively.

Western immunoblotting was performed by a procedure described elsewhere (18). Alkaline phosphatase-conjugated affinity-purified anti-human, -rabbit or -mouse

immunoglobulin G (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) were used at a 1:1,000 or 1:2,000 dilution as a secondary antibodies.

**Immunization of Mice and *E. chaffeensis*-Challenge.** A band of recombinant OMP-1 separated from pET29aOMP-1 by SDS-PAGE was excised, minced, and mixed with an equal volume of Freund's incomplete or complete adjuvant. Nine BALB/c male mice (6 weeks old) were divided into two groups. Five mice were intraperitoneally immunized totally four times at 10-day intervals; twice with a mixture of the minced gel with recombinant OMP-1 (30 to 40 µg of protein per mouse each time) and incomplete adjuvant, and twice with a mixture of the recombinant protein (the same amount as before) and complete adjuvant. As nonimmunized mice, another four mice were intraperitoneally injected with a mixture of the minced gel without protein and the respective adjuvants. For *E. chaffeensis*-challenge, approximately  $10^7$  infected DH82 cells were disrupted by sonication in serum-free DMEM (GIBCO-BRL) and centrifuged at  $200 \times g$  for 5 min. The supernatant was adjusted to a final volume of 5 ml, and 0.3 ml was inoculated intraperitoneally into each mouse at 10 days after the last immunization. After 5 days, the mice were sacrificed and the blood specimens were collected for detection of *E. chaffeensis* DNA by PCR.

The infectivity of *E. chaffeensis* in the inoculum was assessed by the infected cell counting units (ICU) method (19). Serial 10-fold dilutions (0.15 ml each) of the inoculum were added to uninfected DH82 cells in a Lab-Tek tissue culture chamber (Nunc Inc. Naperville, IL). After 3 days of incubation, the percentage of infected cells was determined. Total cell number per well was determined by counting trypsinized (0.1%)-uninfected DH82 cells. The ICU in 0.3 ml of the original suspension was determined by the following formula: ICU = (percentage of infected cells)  $\times$  (1/100)  $\times$  (total cell number)  $\times$  (1/dilution)  $\times$  (0.3/0.15).

**Detection of *E. chaffeensis* 16S RDNA in Ehrlichia-Challenged Mice.** Approximately 1 ml of blood collected in an EDTA tube from each mouse was centrifuged at  $600 \times g$  for 15 min. The buffy coat and blood plasma obtained were used for DNA preparation and western blot analysis, respectively. Total DNA was prepared from 0.2 ml of the buffy coat with a QIAamp blood kit (QIAGEN, Inc., Chatsworth, CA). This DNA was used as the template in the PCR for detection of *E. chaffeensis* DNA. The primers used were HE1 (5'-CAATTGCTTAT-AACCTTTTGGT TATAAAT-3') and HE3 (5'-TATAGGTACCGTCATTATCTTCCCTAT-3'), which are specific for *E. chaffeensis* 16 RDNA and which generated the expected 389-bp fragment (20). The PCR was performed by the procedure as described elsewhere (21).

## RESULTS

**Identification of Major Outer Membrane Proteins of *E. chaffeensis* and Analysis of the NH<sub>2</sub>-Terminal Amino Acid Sequences.** In a preliminary test for isolation of an ehrlichial outer membrane, purified *E. chaffeensis* Arkansas was treated with different concentrations (0.05, 0.1, and 0.2%) of Sarkosyl. SDS-PAGE analysis of the resultant soluble supernatant and insoluble precipitate showed that with 0.1% Sarkosyl treatment (Fig. 1A), the insoluble precipitate contained several 23- to 29-kDa major proteins (considered as a 30-kDa cluster), whereas the 55-kDa protein (HSP60 homolog [9]) and several other minor proteins were in the

soluble supernatant. Treatment of *E. chaffeensis* with 0.05% Sarkosyl resulted in a PAGE profile similar to that obtained with 0.1% Sarkosyl treatment and 0.2% Sarkosyl solubilized almost all proteins (data not shown). With 0.1% Sarkosyl treatment of *E. canis*, the result was similar to that obtained with *E. chaffeensis* (Fig. 1B). Transmission electron microscopy revealed ehrlichial outer membrane vesicles of various sizes in the 0.1% Sarkosyl-insoluble precipitate of *E. chaffeensis* (Fig. 2). These results indicate that treatment of ehrlichiae with Sarkosyl at a concentration of 0.1% (or 0.05 %) effectively separates the ehrlichial outer membrane proteins from other proteins. To analyze in detail the major proteins in the 30-kDa cluster, proteins in the 0.1% Sarkosyl-insoluble precipitate were separated by a reversed-discontinuous SDS-PAGE (Fig. 3). The results obtained showed that this cluster consists of at least five major proteins with molecular masses of 29, 28, 27, 25, and 23 kDa on PAGE. The NH<sub>2</sub>-terminal amino acid sequences of all of these five major proteins were chemically determined. The amino acid sequence of OMP-1 is NH<sub>2</sub>-DPAGSGINGNFYISGYMP-COOH. The NH<sub>2</sub>-terminal amino acid sequence of 23-kDa protein was homologous to the sequence from amino acids 54 to 68 predicted from open reading frame (ORF) of *E. chaffeensis omp-1* described below (Fig. 4 and Fig. 5A). The sequences of 25-kDa and 27-kDa proteins at the NH<sub>2</sub> termini were homologous (Fig. 5B). On the other hand, we recently cloned genes encoding Gen proteins homologous to OMP-1, but not identical, from *E. chaffeensis* genomic DNA with a labeled PCR-amplified *omp-1* as a probe. The NH<sub>2</sub>-terminal amino acid sequence of 29-kDa protein determined chemically was homologous to a part of the predicted amino acid sequence of the Gen-1, one of Gen proteins (Fig. 5C). This result suggests that *E. chaffeensis* in DH82 cells coexpresses several similar proteins with different molecular masses.

**DNA and Predicted Amino Acid Sequence of PCR-Amplified *omp-1*.** An almost-full-length fragment of *omp-1* amplified with f28pl and r28pl primers was cloned (pCRIIOMP-1) and sequenced (Fig. 4). The insert fragment of a pCRIIOMP-1 clone encoded a protein consisting of 251 amino acid residues (including both PCR primer regions). The predicted molecular mass of this protein was 27,685 Da. The protein encoded on the insert does not contain five amino acid residues (DPAGS) that correspond to the NH<sub>2</sub> terminus of the native OMP-1. The predicted amino acid sequence, including DPAGS, revealed that this protein is rich in Gly (11.32 mol %) and Ser (10.54 mol %), and that its estimated isoelectric point is 5.06.

**Overexpression of OMP-1 and Its Immunoreactivity.** A clone, pET29aOMP-1, that was constructed with an insert of pCRIIOMP-1 overexpressed a large amount of recombinant OMP-1 (Fig. 7A). The pET29aOMP-1 clone produced a protein larger than native OMP-1 because it included 35 peptides from the pET29a vector upstream of Gly at the NH<sub>2</sub> terminus of OMP-1 derived from the pCRIIOMP-1 insert. The predicted molecular mass of the expressed protein was 31,063 Da. The recombinant OMP-1 was recognized strongly by convalescent-phase serum from a patient with clinical signs of human ehrlichiosis (Fig. 7B, lane 2). The patient serum cross-reacted predominantly to 28-kDa native OMP-1 and 29-kDa protein of purified *E. chaffeensis* (lane 3) and to the 30-kDa major protein of *E. canis* (lane 1). Using-rabbit anti-recombinant OMP-1 serum, Western immunoblot analysis revealed three strongly cross-reactive proteins of 29 kDa, 28 kDa (native OMP-1), and 25 kDa in *E. chaffeensis*, and 30-kDa protein in *E. canis* (Fig. 9). These are not degradation products of larger proteins, since the NH<sub>2</sub>-terminal amino acid sequences of these proteins were not identical to any parts of the



OMP-1 amino acid sequences. These facts suggest that *E. chaffeensis* in DH82 cells coexpresses several homologous proteins with different molecular masses, i.e., that these proteins are members of a multi-sized protein antigen family.

**Protection against *E. chaffeensis* Challenge in Mice Immunized with Recombinant OMP-1 and Protein Antigens Recognized by the Immunized Mice.** The anti-*E. chaffeensis* IFA titer of sera collected from the retroorbital plexus of immunized mice was 1:160 at the time of challenge. Sera from the control group of mice were negative. Recombinant OMP-1-immunized mice and nonimmunized mice were challenged with an *E. chaffeensis* inoculum of  $1.28 \times 10^6$  ICU per mouse. Protection was assessed by PCR, which detected a 16S rDNA fragment specific to *E. chaffeensis* (389 bp) in the buffy coat from each mouse at 5 days postchallenge. Day 5 is the earliest time at which establishment of ehrlichial infection can be investigated by PCR without the influence of residual DNA from the ehrlichiae used as the challenge. An *E. chaffeensis*-specific fragment was observed in all nonimmunized mice but not in any immunized mice, showing that immunization with recombinant OMP-1 protects mice from ehrlichial infection (Fig. 9).

By Western blot analysis *chaffeensis*-challenged mice which were previously sera from two immunized mice predominantly reacted with 29- and 28-kDa (native OMP-1) proteins in purified *E. chaffeensis* (Fig. 10A and B) while sera from the other two immunized mice were reacted with three major proteins of 29 kDa, 28 kDa (native OMP-1), and 25 kDa (Fig. 10C and E). The antigen profile in panel C was similar to that of the rabbit anti-recombinant OMP-1 serum in Fig. 8. The reactivity of the native OMP-1 on blots was strongest among all reactive proteins. The blood plasma from one immunized mouse (Fig. 10D) was reactive to recombinant OMP-1 but not to any proteins of *E. chaffeensis*, although the plasma was IFA positive with *E. chaffeensis* antigen and the mouse was protected against the ehrlichial infection. It is unknown why even native OMP-1 did not react with the blood plasma of this mouse. However, these results showed clearly that the antibody response is different in each mouse despite of utilization of an inbred strain for this study. The blood plasma from all four nonimmunized mice did not react to any proteins in 30-kDa cluster in the Western blot analysis (data not shown), indicating that immunoreaction to 25, 28 and/or 29 kDa proteins in immunized mice is induced by the immunization with recombinant OMP-1 rather than by the challenge with live *E. chaffeensis*. Thus, the presence of immunocross-reactivities of 25-, 28-, and 29-kDa proteins with blood plasma from immunized mice supports our conclusion that these proteins are members of multi-sized protein antigen family of *E. chaffeensis*.

## DISCUSSION

In this study, we identified five 23- to 29-kDa *E. chaffeensis* major proteins in outer membrane enriched by 0.1 % Sarkosyl treatment and characterized a PCR-amplified omp-1 gene encoding one of the major proteins, 28-kDa OMP-1. The relationships among the five major outer membrane proteins, 23 kDa, 25 kDa, 27 kDa, 28 kDa (OMP-1), and 29 kDa are summarized as follows. (i) The 23-kDa major protein has the similar amino acid sequence to that of 28-kDa OMP-1. (ii) The 25-kDa major protein has a common antigenic epitopes with 28-kDa OMP-1. (iii) The 27-kDa major protein possesses the similar NH<sub>2</sub>-terminal amino acid sequence to that of 25-kDa protein. (iv) The 29 kDa major protein has a common epitopes with 28-kDa

OMP-1. Accordingly, we defined these proteins as a multi-sized protein antigen family, and the 28-kDa OMP-1 is a member of the family. In fact, we have succeeded in cloning several DNA fragments with ORFs similar but not identical, to that of *omp-1* from *E. chaffeensis* genomic DNA by using labeled-PCR-amplified *omp-1* as a probe. The cloned 3.6-kb fragment contained tandemly repeated 5'-truncated, two complete, and 3'-truncated ORFs, all of which are homologous to that of *omp-1*; that is, *omp-1* has multiple gene copies. Gen-1 is one of copies, which possesses a homologous sequence to NH<sub>2</sub>-terminal amino acid sequence of 29-kDa protein. The presence of these multigene copies strongly supports our conclusion that *E. chaffeensis* coexpresses multiple homologous proteins.

We looked for in other *Ehrlichia* spp. proteins reactive with rabbit anti-*E. chaffeensis* recombinant OMP-1 serum. Rabbit anti-recombinant OMP-1 serum cross-reacted with three proteins of the homologous strain of *E. chaffeensis* and the 30-kDa protein of *E. canis* in group 1. We recently found that the *E. canis* 30-kDa protein gene may also have multiple gene copies. The predicted amino acid sequences of partial ORFs in the two DNA fragments of *E. canis*, which were cloned after PCR amplification with two different primer pairs corresponding to the sequence of *omp-1*, were similar but not identical to each other and both were homologous to the amino acid sequence of *omp-1*.

The question is why such various homologous outer membrane proteins of approximately 30 kDa exist in *E. chaffeensis* and *E. canis*. Our previous and preliminary studies led us to speculate as follows. Previously, we observed that acute-phase sera (before 30 days postinoculation) from several *E. canis*-infected dogs reacted strongly with a 30-kDa protein but weakly with a 31 kDa protein. However, with chronic-phase serum (after 60 days postinoculation) from the same infected dog, the 31-kDa protein reacted strongly and the reactivity of 30-kDa protein decreased (31). These results suggest that the ehrlichiae may regulate the expression of homologous proteins on their surfaces in order to elude host immune recognition. On the other hand, our preliminary study found that several <sup>125</sup>I- labeled outer membrane proteins of ~30-kDa of *E. chaffeensis* bound to paraformaldehyde-fixed DH82 cells. This suggests that the OMP-1 family may consist of proteins that participate in the attachment of ehrlichiae to eukaryotic host cells. Consequently, the conserved amino acid sequences in these multiproteins may be necessary for attachment of the host cells, and the antigenic polymorphism may be required for eluding host immune recognition.

We demonstrated that recombinant OMP-1 protects mice from *E. chaffeensis* infection, suggesting that this protein may be a candidate for development of a vaccine and a diagnostic antigen for the ehrlichiosis.

This work was supported by grant ROI A133123 from National Institutes of Health.

1. Maeda, K., Markowitz, N., Hawley, R. C., Ristic, M., Cox, D. & McDade, J.E. (1987) *N.Engl. J. Med.* 316, 853-856.
2. Anderson, B. E., Dawson, J. E., Jones, D. C. & Wilson, K. E. (1991) *J. Clin. Microbiol.* 29, 2838-2842.
3. Dumler, J. S., Dawson, J. E. & Walker, D. H. (1993) *Hum. Pathol.* 24, 391-396.
4. Eng, T. R., Harkess, J. R., Fishbein, D. B., Dawson, J. E., Greene, C. N., Redus, M. A. & Satalowich, E. T. (1990) *JAMA* 264, 2251-2258.
5. Sumner, J. W., Sims, K. G., Jones, D. C. & Anderson, B. E. (1993) *Infect. Immun.* 61,

- 3536-3539.
6. Rikihisa, Y., Ewing, S. A. & Fox, J. C. (1994) *J. Clin. Microbiol.* **32**, 2107-2112.
7. Chen, S.-M., Dumler, J. S., Feng, H.-M. & Walker, D. H. (1994) *Am. J. Trop. Med. Hyg.* **50**, 52-58.
8. Dumler, J. S., Chen, S.-M., Asanovich, K., Trigiani, E., Popov, V. L., and Walker, D. H. (1995) *J. Clin. Microbiol.* **33**, 1704-1711.
9. Rikihisa, Y., Zhang, Y. & Park, J. (1994) *Infect. Immun.* **62**, 5126-5132.
10. Khan, M. N., Khan, R. J. & Posner, B. I. (1981) *Anal. Biochem.* **117**, 108-112.
11. Ohashi, N., Tamura, A., Ohta, M. & Hayashi, K. (1989) *Infect. Immun.* **57**, 1427-1431.
12. Rikihisa, Y., Pretzman, C. I., Johnson, G. C., Reed, S. M., Yamamoto, S. & Andrew, F. (1988) *Infect. Immun.* **56**, 2960-2966.
13. Wells, M. Y. & Rikihisa, Y. (1988) *Infect. Immun.* **56**, 3209-3215.
14. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) *J. Mol. Biol.* **215**, 403-410.
15. Ohashi, N., Nashimoto, H., Ikeda, H. & Tamura, A. (1992) *J. Biol. Chem.* **267**, 12728-12735.
16. Koehler, J. E., Birkelund, S. & Stephens, R. S. (1992) *Mol. Microbiol.* **6**, 1087-1094.
17. Pretzman, C. I., Rikihisa, Y., Ralph, D., Gordon, J. C. & Bech-Nielsen, S. (1987) *J. Clin. Microbiol.* **25**, 31-36.
18. Rikihisa, Y., Ewing, S. A., Fox, J. C., Siregar, A. G., Pasariba, F. H. & Malole, M. B. (1992) *J. Clin. Microbiol.* **30**, 143-148.
19. Ohashi, N., Koyama, Y., Urakami, H., Fukuhara, M., Tamura, A., Kawamori, F., Yamamoto, S. & Yoshimura, K. (1996) *Microbiol. Immunol.* In press.
20. Anderson, B. E., Sumner, J. W., Dawson, J. E., Tzianabos, T., Greene, C. R., Olson, J. G., Fishbein, D. B., Olsen-Rasmussen, M., Holloway, B. P., George, E. H. & Azad, A. F. (1992) *J. Clin. Microbiol.* **30**, 775-780.
21. Wen, B., Rikihisa, Y., Fuerst, P. A. & Chaichanasiriwithaya, W. (1995) *Int. J. Syst. Bacteriol.* **45**, 315-318.
22. Van Vliet, A. H. M., Jongejan, F., Vann Kleef, M. & Vann der Zeijst, B. A. M. (1994) *Infect. Immun.* **62**, 1451-1456.
23. Mahan, S. M., Tebele, N., Mukwedey, D., Semu, S., Nyathi, C. B., Wassink, L. A., Kelly, P. J., Peter, T. & Barbet, A. F. (1993) *J. Clin. Microbiol.* **31**, 2729-2737.
24. Oberle, S. M. & Barbet, A. F. (1993) *Gene* **136**, 291-294.
25. Palmer, G. H., Eid, G., Barbet, A. F., McGuire, T. C. & McElwain, T. F. (1994) *Infect. Immun.* **62**, 3808-3816.
26. Rikihisa, Y., Zhi, N., Wormser, G. P., Wen, B., Horowitz, H. W., & Hechemy, K. E. (1996) *J. Infect. Dis.* In press.
27. Pretzman, C. T., Ralph, D., Stotherd, D., Fuerst, P. A. & Rikihisa, Y. (1995) *Int. J. Syst. Bacteriol.* **45**, 315-318.
28. Van Vliet, A. H. M., Jongejan, F. & van der Zeijst, B. A. M. (1992) *Int. J. Syst. Bacteriol.* **42**, 494-498.
29. Dame, J. B., Mahan, S. M. & Yowell, C. A. (1992) *Int. J. Syst. Bacteriol.* **42**, 270-274.
30. Barbet, A. F. (1995) *Vet. Parasitol.* **57**, 43-49.
31. Iqbal, Z. & Rikihisa, Y. (1994) *J. Clin. Microbiol.* **32**, 1644-1649.

32. Hass, R. & Meyer, T. F. (1986) *Cell* 44, 107-115.

150053531.091997

## FIGURE LEGENDS

FIG. 1. SDS-PAGE of the insoluble precipitate and the soluble supernatant fraction after 0.1% Sarkosyl treatment of purified *E. chaffeensis* (A) and *E. canis* (B). Proteins at 20 µg of purified whole organism lysates (lane 2), 7 to 13 µg of Sarkosyl-insoluble precipitate enriched with the outer membrane (lane 3), and 7 to 13 µg of Sarkosyl-soluble supernatant (lane 3) were stained with Coomassie blue after SDS-PAGE. Molecular markers are shown in lane 1 and indicated in kilodaltons. Brackets indicate a 30-kDa cluster of major outer membrane proteins.

FIG. 2. Electron microscopy of the insoluble precipitate after 0.1% Sarkosyl treatment of the whole *E. chaffeensis* organism. Note outer membrane vesicles of various sizes. (Bar = µm).

FIG. 3. Major outer membrane proteins in the 30-kDa cluster resolved from the Sarkosyl-insoluble precipitate of *E. chaffeensis* by a reversed-discontinuous SDS-PAGE. An SDS-polyacrylamide gel consisting of a 17% gel on top of a 12% gel was used. The Sarkosyl-insoluble precipitate (40 µg per lane) enriched with outer membrane derived from purified *E. chaffeensis* was blotted onto a nitrocellulose sheet and stained with amido black (lanes 1-6). Five protein bands of 23 to 29 kDa on every lane of this sheet were cut, and the NH<sub>2</sub>-terminal amino acid sequence of each protein was analyzed. Molecular masses of representative major outer membrane proteins are indicated in kilodaltons.

FIG. 4. DNA sequence of pCRIIOMP-1 insert and the predicted amino acid sequence of the ORF. Amino acid residues underlined at amino acid positions 1 to 20 and 53 to 68 are the NH<sub>2</sub>-terminal amino acid sequence of native OMP-1 determined chemically and the sequence homologous to the NH<sub>2</sub>-terminal amino acid sequence of 23-kDa protein respectively. Five amino acid residues at the NH<sub>2</sub> terminus of native OMP-1, which were not included in the ORF of the pCRIIOMP-1 insert, are indicated by boldface type. Arrows indicate the annealing positions of the primer pair designed for PCR amplification of *omp-1*.

FIG. 5. Characteristics of the NH<sub>2</sub>-terminal amino acid sequences of native 23-, 25-, 27-, and 29-kDa major OMPs of *E. chaffeensis*. Similarities were seen in the sequences between 23-kDa protein and OMP-1 (A), in the NH<sub>2</sub>-terminal sequences between 25-kDa and 27-kDa proteins (B), and in the sequence between 29-kDa protein and Gen-I (C). Identical and conserved amino acids are indicated by colons and periods, respectively, and a gap is indicated by a dash. Amino acids are denoted by the one-letter amino acid code.

FIG. 6. Alignment of deduced amino acid sequences of *E. chaffeensis* OMP-1, *C. ruminantium* MAP-1, and *A. marginate* MSP-4. Aligned positions of amino acids identical to those in *E. chaffeensis* OMP-1 are indicated by asterisks. Gaps indicated by dashes are introduced for optimal alignment of all three proteins.

FIG. 7. Overexpression of *E. chaffeensis* OMP-1 (A) and its immunoreactivity with convalescent-phase serum from a patient with human ehrlichiosis (B). (A) Lysates of pET29a-transformed *E. coli* BL21(DE3)pLysS (20 µg, lane 2) and pET29aOMP-1 transformed *E. coli* BL21 (DE3)pLysS (20 µg, lane 3) which were harvested at 4.5 h after induction by Isopropyl-β-D-thiogalactopyranoside were stained with Coomassie blue after SDS-PAGE. An arrowhead indicates overexpressed OMP-1. (B) Proteins from SDS-PAGE gels containing 10 µg of purified *E. canis* lysate (lane 1), 8 µg of pET29aOMP-1-transformed *E. coli* BL21(DE3)pLysS

60059353-091997

(lane 2), and 10 µg of purified *E. chaffeensis* lysate (lane 3) were transferred to a nitrocellulose sheet and incubated with a 1:1,000 dilution convalescent phases serum from a patient. Molecular masses are shown in kilodaltons.

FIG. 8. Western blot analysis with rabbit anti-recombinant *E. chaffeensis* OMP-1 serum. Samples subjected to SDS-PAGE were 10 µg of pET29a-transformed *E. coli* (lane 1), 10 µg of pET29aOMP-1-transformed *E. coli* (lane 2), 20 µg of purified whole *E. chaffeensis* lysate (lane 3), and 20 µg of purified whole *E. canis* lysate (lane 4). These proteins from SDS-PAGE gel were transferred to nitrocellulose sheet and incubated with the 1:300 dilution of the rabbit anti-recombinant OMP-1 serum which was preabsorbed twice with pET29a-transformed *E. coli* at 37°C for 1 h per time. Molecular masses are shown in kilodaltons.

FIG. 9. PCR amplification of a 16S rDNA fragment specific for *E. chaffeensis* in the ehrlichia-challenged mice which were previously immunized with a recombinant OMP-1 or nonimmunized. Template DNA's were prepared from blood buffy coats (0.2 ml) of all challenged mice. An arrow shows the *E. chaffeensis*-specific 16S rDNA fragment (389 bp) obtained by PCR amplification. As a template for the positive control, total DNA from DH82 cells infected with *E. chaffeensis* was used (lane 1); for the negative control, a PCR reaction without template was carried out (lane 2). Four nonimmunized (lanes 3-6) and five immunized mice (lanes 7-11) that were injected with a mixture of adjuvants and minced polyacrylamide gel without and with recombinant OMP-1, respectively, were challenged with  $1.28 \times 10^6$  ICU of *E. chaffeensis*. A DNA 1-kb ladder is shown in lane 12.

FIG. 10. Western blot analysis with blood plasma obtained from the five *E. chaffeensis*-challenged mice which were previously immunized with recombinant *E. chaffeensis* OMP-1 as shown in Fig. 9. Antigens subjected to SDS-PAGE were 10 µg of pET29aOMP-1-transformed *E. coli* (lane 1) and 20 µg of purified *E. chaffeensis* lysate (lane 2). These proteins after SDS-PAGE were transferred to a nitrocellulose sheet and incubated with the 1:200 dilution of the blood plasma from each mouse corresponding to lane 7 to 11 in Fig. 9 (A to E). The blood plasma from four nonimmunized mice in lane 3 to 6 of Fig. 9 was not reactive to any proteins in 30-kDa cluster of *E. chaffeensis* (data not shown). All blood plasma were preabsorbed twice with pET29a-transformed *E. coli* at 37°C for 1 h per time. Molecular masses are shown in kilodaltons.

50059353.091997

5055353-091907

## SUMMARY OF THE INVENTION

In accordance with the present invention, isolated proteins from the outer membrane of *Erlichia chafeenis* are provided. One of the outer membrane proteins, designated OMP-1 has a molecular weight of about 28 kDa; another outer membrane protein has a molecular weight of about 23 kDa protein; another outer membrane protein has a molecular weight of about 25 kDa protein; another outer membrane protein has a molecular weight of about 27 kDa protein, and another outer membrane protein has a molecular weight of about 29 kDa.. The isolated outer membrane proteins from *E. chafeenis*, particularly OMP-1, are immunogenic and are thus, useful for preparing antibodies. Such antibodies are useful for immunolabeling isolates of *E. chafeenis* and for detecting the presence of *E. chafeenis* in body fluids, tissues, and particularly in the monocytes and macrophages of individuals, including but not limited to individuals exhibiting symptoms of human ehrlichiosis. The isolated outer membrane proteins, particularly OMP-1A, are also useful for detecting antibodies to *E. chafeenis* in the blood of individuals with clinical signs of human ehrlichiosis. The isolated outer membrane protein, particularly OMP-1, are also useful in raising antibodies to assist in protecting against ehrlichiosis and in a vaccine for protecting against ehrlichiosis.

In accordance with the present invention an isolated outer membrane protein from *Erlichia canis* is also provided. This protein, designated has a molecular weight of about 30 kDa. This protein is immunogenic and is, thus, useful for preparing antibodies that are useful for immunolabeling isolates of *E. canis*. This protein is also useful for diagnosing canine ehrlichiosis and in a vaccine for protecting mammals, particularly members of the family Canidae, most particularly dogs, from canine ehrlichiosis.

The present invention also provides nucleotide sequences encoding proteins, OMP-1 OMP-1A, OMP-1B, OMP-1C, OMP-1D, OMP-1E, and OMP-1F. The present invention also provides nucleotide sequences encoding the 30 kDa outer membrane protein from *E. canis*. Such sequences are useful for preparing the outer membrane proteins, particularly large amounts of highly purified proteins.

The present invention also relates to a method of using the nucleotide sequences which encode OMP-1A, OMP-1C, OMP-1D, OMP-1E , OMP-1 F, and the 30 kDa outer membrane

protein from *E. canis* to prepare these proteins or fragments, particularly immunogenic fragments thereof.

The present invention also relates to a method the isolated recombinant proteins made by such methods.

The present invention is also relates to an assay for diagnosing canine ehrlichiosis using the 30 kDa outer membrane protein of the present invention.

Isolated Polynucleotides Encoding OMP-1, OMP-1A, OMP-1B, OMP-1C, OMP-1D, OMP-1F and the OMP from *E. Canis*

In one aspect, the present invention, provides isolated polynucleotides that encode the outer membrane proteins, OMP-1, OMP-1A, OMP-1B, OMP-1C, OMP-1D, OMP-1F from *E. chafeensis* and the OMP of approximately 30 kDa from *E. Canis* or immunogenic fragments thereof.

The polynucleotide may be single stranded or double stranded. The polynucleotide may be a DNA or RNA molecule, preferably a DNA molecule, and comprises a sequence which codes for the respective outer membrane protein. Preferably, the polynucleotide encodes at least the mature form of outer membrane protein. The polynucleotide optionally further comprise a leader sequence and encode an outer membrane preprotein that is processed and secreted from cells as the mature protein. The polynucleotide of the present invention may also be fused in frame to a marker sequence which allows for purification of the corresponding outer membrane protein.

In one embodiment, the polynucleotide for OMP-1 encodes a protein comprising the amino acid sequence shown in FIG. 4A or 4B (Section A) or an allelic variant thereof. In one embodiment the polynucleotide for OMP-1A, OMP-1B, OMP-1C, OMP-1D, OMP-1E, OMP-1F encodes a protein comprising the amino acid sequence shown in Fig 8 (Section B). In one embodiment, the polynucleotide which encodes the 30 kDa protein from *E. canis*. Examples of such nucleic acid sequences are shown in Figs 4, 8 and 14. The present invention also relates to polynucleotide comprising a sequence having at least 80%, preferably at least 90%, more preferably at least 95%, most preferably at least 97% identity or complementarity with the nucleotide sequences shown in Fig. 4A, 4B, Fig 8, and Fig. 14. The polynucleotide of the present invention further relates to polynucleotide sequences which hybridize under stringent conditions to the nucleotide sequence shown in Figs 4, Fig 8, and Fig. 14.



766T60-ES65059

The polynucleotides of the present invention are useful for producing the outer membrane proteins of *E. chafeenis* and *E. canis*. For example, an RNA molecule encoding the outer membrane protein is used in a cell-free translation systems to prepare the outer membrane protein. Alternatively, a DNA molecule encoding the outer membrane protein is introduced into an expression vector and used to transform cells. Suitable expression vectors include for example chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40, bacterial plasmids, phage DNAs; yeast plasmids, vectors derived from combinations of plasmids and phage DNAs, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. The DNA sequence is introduced into the expression vector by conventional procedures.

Accordingly, the present invention also relates to recombinant constructs comprising one or more of the sequences as broadly described above. The constructs can be in the form of a vector, such as a plasmid, phagemid, or viral vector, into which a sequence that encodes the outer membrane protein has been inserted.

In the expression vector, the DNA sequence which encodes the outer membrane protein is operatively linked to an expression control sequence, i.e., a promoter, which directs mRNA synthesis. Representative examples of such promoters, include the LTR or SV40 promoter, the *E. coli* lac or trp, the phage lambda PL promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or in viruses. The promoter may also be the natural promoter of the outer membrane protein coding sequence. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. Preferably, the recombinant expression vectors also include an origin of replication and a selectable marker, such as for example, the ampicillin resistance gene of *E. coli* to permit selection of transformed cells, i.e. cells that are expressing the heterologous DNA sequences.

The polynucleotide sequence encoding the outer membrane protein is incorporated into the vector in frame with translation initiation and termination sequences, and optionally, with a leader sequence capable of directing secretion of the translated protein into the periplasmic space or extracellular medium. Optionally, the sequence encodes a fusion outer membrane protein which includes an N-terminal or C-terminal peptide or tag that stabilizes or simplifies purification of the expressed recombinant product. Representative examples of such tags include

sequences which encode a series of histidine residues, the Herpes simplex glycoprotein D, or glutathione S-transferase.

Suitable hosts cells are, for example, bacterial cells, such as *E coli*, fungal cells, such as yeast; and animal cells such as Chinese Hamster Ovary cells. Host cells are transformed with the expression vectors of this invention and cultured in conventional nutrient media. Such media optionally contains additional compounds, such as for example compounds that induce promoters, such as for example isopropyl- $\beta$ -D-thiogalactoside which induces the Lac promoter, or compounds, such as for example, ampicillin, which allows for selection of transformants.

In addition to serving as a template in the production of the outer membrane, the polynucleotide which encodes the outer membrane protein is useful as a probe for isolating other genes that encode the outer membrane proteins of other ehrlichiae species. The outer membrane protein encoding polynucleotide or smaller portions thereof, such as for example oligonucleotides of 200 to 2000 nucleotides can also be radiolabeled and used as hybridization probes.

The proteins OMP-1A, OMP-1B, OMP-1C, OMP-1D, OMP-1F from *E. chafeenis* and the OMP from *E. Canis*

The present invention also the proteins OMP-1A, OMP-1B, OMP-1C, OMP-1D, OMP-1F from *E. chafeenis* and the OMP from *E. Canis*. In one embodiment, OMP-1A, OMP-1B, OMP-1C, OMP-1D, OMP-1E, and OMP-1F have the amino acid sequences shown in FIG. In one embodiment the outer membrane protein from *E. canis* has the amino acid sequence shown in Fig. In other embodiments the respective outer membrane protein comprises an allelic variant or a derivative of the amino acid sequence s shown in Fig. 4, 8, and 14. In another embodiment the outer membrane protein is a fusion protein that further comprises additional amino acids fused to the amino terminus or carboxy terminus of PMR. The additional amino acids aid in, for example, purification of the protein. In addition to naturally occurring allelic forms, the outer membrane protein as described herein embraces non-naturally occurring allelic forms of outer membrane , where one or more of the amino acids have been replaced by conservative amino acid residues, typically by using direct synthesis or recombinant techniques.

60050353-091997

### Preparing the Outer Membrane Proteins

The outer membrane proteins of the present invention are synthetically produced by conventional peptide synthesizers. The outer membrane proteins are also produced using cell-free translation systems and RNA molecules derived from DNA constructs that encode the outer membrane protein. Alternatively, the outer membrane protein is made by transfecting host cells with expression vectors that comprise a DNA sequence which encodes the outer membrane protein and then inducing expression of the outer membrane protein in the host cells.

The outer membrane protein is expressed in suitable host cells, such as for example, mammalian cells, yeast, bacteria, or other cells under the control of suitable promoters. Following transformation of the suitable host strain and growth of the host strain to an appropriate cell density, the cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification of the outer membrane protein.

The recombinant outer membrane protein that is expressed in a host cell culture is usually isolated by initial extraction from cell pellets or from cell culture medium, followed by salting-out, and one or more chromatography steps, including aqueous ion exchange chromatography, size exclusion chromatography steps, and high performance liquid chromatography (HPLC).

The outer membrane proteins, particularly OMP-1A, and the 30 kDa protein from *E. canis* are useful for preparing antibodies for immunolabeling isolates of *E. chafeenis* and *E. canis* respectively. Such antibodies are useful tools for diagnosing human ehrlichiosis and canine ehrlichiosis, respectively. The outer membrane proteins, particularly OMP-1A, and the 30 kDa protein from *E. canis* are useful for preparing vaccines to protect humans and dogs respectively from ehrlichiosis.

Antigens:

1. E. chaffeensis recombinant 28 kDa protein
2. Purified E. canis, Oklahoma strain
3. Purified E. canis, Cujo or others
4. E. canis recombinant 30 kDa protein

Sera:

1. Dog anti-E. chaffeensis, Oklahoma strain serum
2. Normal dog serum
3. Human anti-E. chaffeensis serum
4. Normal human serum
5. Clinical E. canis IFA positive sera
6. Clinical E. canis IFA negative sera
7. Experimentally infected dog sera

Reagents:


1. PBS
2. T-PBS: 0.05% Tween 20 PBS
3. Secondary antibody:
  - Peroxidase conjugated anti-dog IgG
  - Peroxidase conjugated anti-dog IgM
  - Peroxidase conjugated anti-human IgG
  - Peroxidase conjugated anti-human IgM
4. Peroxidase color development solution
  - 3,3'-diaminobenzidine.4 HCl (Nakaraikagaku-don't use others) 0.3g
  - CH<sub>3</sub>COONa. 3H<sub>2</sub>O 1.0 g
  - Dist H<sub>2</sub>O 100 ml
  - 1N-NaOH approximately 2.5 ml to make pH 6.2
  - 3 % H<sub>2</sub>O<sub>2</sub> 0.7 ml

Make one day before reaction. Cover the bottle with aluminum foil to prevent light. Keep in the dark. Before use filter with filter paper. You can use it up to 1 week.
5. 0.4M H<sub>2</sub>SO<sub>4</sub>: Dilute the concentrated H<sub>2</sub>SO<sub>4</sub> 50 times.

Dot Immunoassay:

1. Cut nitrocellulose membrane to fit in the apparatus. Never touch the membrane with your finger. The membrane is brittle and handle carefully.
2. Soak the membrane in PBS for 5 min by gently placing the sheet on the surface of PBS solution. Don't trap air bubbles.
3. Set the membrane in the dot-blot apparatus and aspirate for 5 min.
4. Carefully add antigen suspension (10 ul) in each well. Don't poke a hole in the membrane. Don't attach the droplet to the wall of the well.
5. Cover the empty wells with saran wrap.
6. Aspirate for 5 min to make antigen bound.
7. Take out nitrocellulose membrane from the apparatus.
8. Soak the membrane in T-PBS at 37 C for 30 min.
9. Cut the membrane in strips. Cut the corner of the strip to identify the orientation.
10. Dry the membrane. Place the membrane in the sandwich bag and keep it in a refrigerator.
11. Soak the dried membrane strip with antigen in T-PBS for 2-3 min.
12. Incubate the strip with the serum serially diluted. 3 ml /strip at room temp. for 60 min.
13. Wash the membrane in T-PBS for 3 times, 10 min each.
14. Incubate with peroxidase conjugated anti dog (or human) IgG or IgM diluted 2,000 fold in T-PBS at room temp. for 30 min.
15. Rinse the membrane like 13. Then rinse with dist H<sub>2</sub>O
16. Soak the membrane in developing solution for 1 min. or longer at room temp.
17. Soak the membrane in 0.4 M H<sub>2</sub>SO<sub>4</sub> for 2 min to stop the reaction
18. Rinse with tap water.
19. Dry between filter paper.
20. Densitometric analysis of the membrane.

Fig 1



60059353.091997

1440

60059353.091997




Fig. 2

1377

6005353.09197

Fig. 3 Fig. 3



1260

Fig 4A

24



**ГОРЬКАТА ПАТЯГОНАТИТЕЦЯ**

60  
23

150  
99

240  
03  
220

420

243  
510  
175

175  
600  
203

690  
222750  
130

27

266160" ESE65009

~~Fig 5~~ Fig 5

(A)	1	15	(B)	1	13
23kDa	NSPENTFNPVNYSPK		27kDa	MNILDVDG--FTQAY	
	.....			.....	
OMP-1	SSPNQVFTVSNYSPK		25kDa	MNLIITQQAIDFTARA	
	54	68		1	15
(C)	1	14			
29kDa	DAVQDDNKKGFYI				
	.....				
Gen-1	DPVQDDNISGNFYI				
	26	39			

Fig 2

206160-35665009


Fig 6

29

OMP-1 10 20 30 40 50  
DPAAGIN--GNPTI SCRYMPSASH FGUFBAKEER NTTVGVFLK  
NAF-1 VIOEN-P-----VBYV A\*\*\*\*\*RMIDDS RD\*NA\*...  
NAF-1 S\*MSHEVASE GGVNG\*S\*V GAN\*S\*APPS VTS\*DMR\*SS RE\*BYR\*YD  
MSP-4 60 70 80 90 100  
QNMDSAISN SBPNVPTVB NISPKYBNP FLGFAAGIY SMOCPRIE  
OMP-1 KD\*VKTBS GNT\*ST\*EK D\*\*\*\*\*V\*\*\*\*\*N\*\*\*\*\*P  
NAF-1 KS---I\*TIID V\*VPAN\*SK\* G\*J\*AFBK\*LI ITS\*D\*V\*...LD\*H\*V\*...  
MSP-4 110 120 130 140 150  
VSETFDVAN GGNKYNENAH RYCALSHNSA ADMSSASNNF VFLKNEGLD  
OMP-1 \*\*\*\*\*R\*P\*G\*...D\*...H\*...DTAGS STAGATS--\*NV\*\*\*N\*...  
NAF-1 A\*RR\*ATIA D\*OYA\*GG\*G SLA\*ITR---\*ANTET\*Y PUV\*IDBITN  
MSP-4 160 170 180 190 200  
ISFIMLNACTD VVGEGRPSP YICAGIGIDL VSM\*ZATNPK ISXOGKGLS  
OMP-1 \*L\*\*\*\*\*IMLD\*H\*V\*...V\*\*\*\*\*V\*\*\*\*\*I\*  
NAF-1 T\*V\*...G\*...LATDL\*V\*...V\*\*\*\*\*AGF \*DISKQVTT\* LA\*R\*...V\*...  
MSP-4 210 220 230 240 250  
YBISPRASVZ ICGHHRVIG NEFRDIPFI- IPTGSLMGR GNPRAIV--I  
OMP-1 \*\*\*\*\*I \*\*\*\*\*R\*...A\*EK VF\*S\*GN\*SS AVS\*GPASA  
NAF-1 \*OPT\*...IIV A\*PY\*GLFO BSK\*...AHN SVNF\*GE\*KA SVNAH\*A---  
MSP-4 260  
LDVCHRCIAC GGRPT\*  
OMP-1 \*\*\*\*\*I \*\*\*\*\*  
NAF-1 ---DY\*PN\* \*A\*L\*S

265T60"ESSE65009


Fig. 7



1350


266T60-ESS65003

Fig. 8



630


Fig. 9.



60059353.091997


630

Fig. 10



1080

60059353-091997



- a Whole *E. coli* host lysate (w)  
b Sonication-insoluble fraction (I) of *E. coli* host  
c Sonication-insoluble fraction (I) of the recombinant clone  
(partially purified rP30)  
d Highly purified rP30 using chromatography

Fig. 1 SDS-PAGE of *E. canis* recombinant rP30 (A) and the purified rP30 (B).







Fig 12

Fig B



Dot blot assay of *E. canis* rP30 using clinical dog sera of different IFA titers (A) and the dog sera preabsorbed with *E. coli* lysate (B)

GAATC

Size 579, Select R1 1

1 GGGATCAACGGGAACCTTACATTAGTGCAAAGTATATGCCAAGTGCCTCACACTTTGGC 60  
 1 G I N G N F Y I S A K Y M P S A S H F G 20  
 61 GTATTTTCAGTTAAAGAGAGAAAAACAACAACACTGGAGTTTTCGGATTAAAAACAAGAT 120  
 21 V F S V K E E K N T T T G V F G L K Q D 40  
 121 TGGGACGGAGCAACAATAAAGGATGCAAGCAGCAGCCACACAATAGACCCAAGTACAATA 180  
 41 W D G A T I K D A S S S H T I D P S T I 60  
 181 TTCTCCATTTCAAATTATTCATTAAATATGAAAACAATCCATTTTAGGGTTTGCAGGA 240  
 61 F S I S N Y S F K Y E N N P P L G F A G 80  
 241 CCTATTGGCTACTCAATGGGTGGTCCAAAGGGTAGAGTTTGAAGTGTCTTACGAAATATTT 300  
 81 A I G Y S M G G P R V B F E V S Y E I F 100  
 301 GATGTAAAAAACCAAGGTAACAGITTACAAGAAGGATGCTCACAAATATTCCGCTTTATCA 360  
 101 D V K N Q G N S Y K N D A H K Y C A L S 120  
 361 AGACACACCGGAGGTATGCCACAAGCCGCTCATCAAAATAAATTTGTCTTCCTAAAAAAT 420  
 121 R H T G C G M P Q A G H Q N K F V F L K N 140  
 421 GAAGGATTACTTGACATATCACTTATGATAAACGCATGTTATGATATAACAATCGACACC 480  
 141 E G L L D I S L M I N A C Y D I T I D S 160  
 481 ATGCTATTTCCTCATATATATGTCCAGGTATTGGTAGTGAAGTACTTTCGATGTTTGAA 540  
 161 M P F S P Y I C A G I G S D L V S M F E 180  
 541 ACTACAAATCCTAAAAATTTTACCAAGGAAAGTTAGGTAAGCTGAATTC 579  
 181 T T N P K I S Y Q G K L G 193

60059353-091997

5841

H1

P30

Fig 14a

-1-

Size 564, Select

1

1 TACATAAGTGGCAATATACATGCCAAGCGTCACATTTTGGAAATTTTTCAGCTAAAGAA 60  
 1 Y I S G K Y M P T A S H F G I F S A K E 20

61 GRACAAAGTTTACTAAGCTATTAGTIGGGTTAGATCAACGATTATCACATAATATTATA 120  
 21 E Q S E T K V L V G L D Q R L S H N I I 40

121 AACAAATATGATACAGCAAGAGCTCTTAAGGTTCAAAATTATTTCATTTAAATACAAAAT 180  
 41 N N N D T A K S L K V Q N Y S F K Y K N 60

181 AACCCATTTCTAGGATTGCAAGAGCTATTGGTTATTCAATAGGCAATTCAGAATAGAA 240  
 61 N P F L G F A R A I G Y S I G N S R I E 80

241 CTAGAAGTATCACATGAAATATTTGATACTAAAAACCCAGGAACAATTATTAAATGAC 300  
 81 L B V S H E I F D T K N P G N N Y L N D 100

301 TCTCACAATATTGCGCTTTATCTCATGGAAGTCACATATGCAGTGATGGAATAGCGGA 360  
 101 S H K Y C A L S H G S H I C S D G N S G 120

361 GATTGGTACACTGCAAAAACGATAAGTTTGTACTTCTGAAAATGAAGGTTTACTTGAC 420  
 121 D W Y T A K T D K F V L L K N E G L L D 140

421 GTCTCATTTATGTTAAACGCATGTTATGACATAACCACTGAAAAAATGCCITTTTCACCT 480  
 141 V S P M L N A C Y D I T T E K M P F S P 160

481 TATATATGTGCAGGTATTGGTACTGATCTCATATCTATGTTTGAGACAACACAAAACAAA 540  
 161 Y I C A G I G T D L I S H F E T T Q N K 180

541 ATATCTTATCAAGGAAGTTAGGTAAAGCCGAAATTC 564  
 181 I S Y Q G K L G T T C C G C T A A G 188

466T60-091497

F12

p30e.

Fig 14b

-1-

38

## INTRODUCTION

*Ehrlichia chaffeensis*, which causes human monocytic ehrlichiosis, is an obligatory intracellular bacterium of monocytes and macrophages, and belongs to the family *Rickettsiaceae*. Human ehrlichiosis was first reported in the United States in 1987 (21). Most patients have a history of tick exposure and develop a febrile illness similar to Rocky Mountain spotted fever. Since 1987, over 400 cases of human ehrlichiosis, detected primarily by serological means, have been reported in 30 states (3, 14, 16).

Recently, several protein antigens of *E. chaffeensis* were identified by western blot analysis using naturally-infected human, experimentally-inoculated dog sera, or monoclonal antibodies (7-10, 13, 31, 35, 40-42). Two of these antigens, namely, heat shock protein (HSP) 60 homolog (35) and 120-kilodalton (kDa) protein (41, 42), have been cloned, sequenced and expressed. Two proteins ranging from 28 to 30 kDa of *E. chaffeensis* were shown to be dominant antigens and were cross-reactive between two *Ehrlichia* spp.: *E. chaffeensis* and *E. canis* (7, 31). Studies with monoclonal antibodies against *E. chaffeensis* showed that 2 to 3 proteins from 22 to 30 kDa react with 3 monoclonal antibodies by western blotting and that these antigens are exposed on the surface of the organism by immunogold labeling of negatively-staining ehrlichiae (8-10, 40). However, why multiple proteins of different molecular sizes react with the monoclonal antibodies has not been answered. These antigens in the 30-kDa range of *E. chaffeensis* were not examined at the molecular level.

In this study, we demonstrated that a potentially immunoprotective 28-kDa protein (designated P28) located on *E. chaffeensis* surface and along with antigenically cross-reactive proteins in 30-kDa range, are encoded by a multigene family.

## MATERIALS AND METHODS

**Organisms and purification.** *E. chaffeensis* Arkansas strain and *E. canis* Oklahoma strain were cultivated in the DH82 dog macrophage cell line (31) and purified by Percoll density

gradient centrifugation as described elsewhere (33, 38).

**Preparation of the ehrlichial outer membrane fraction.** The procedure for *Orientia tsutsugamushi* was followed with modifications (26). Briefly, purified ehrlichiae (100 µg) were suspended with 10 mM sodium phosphate buffer, pH 7.4, containing 0.1% Sodium *N*-lauroyl sarcosine (Sarkosyl) (Sigma, St. Louis, MO), 50 µg/ml each DNase I (Sigma) and RNase A (Sigma), and 2.5 mM MgCl<sub>2</sub>. After incubation at 37°C for 30 min, the sample was separated by centrifugation at 10,000 x g for 1 h into the soluble supernatant and the insoluble precipitate. The insoluble pellet was resuspended 2 to 3 times with 0.1% Sarkosyl and centrifuged. The final pellet was analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), as described elsewhere (32), and by electron microscopy. The pellet was used as the ehrlichial outer membrane fraction. To investigate contamination by ehrlichial inner membrane, succinic dehydrogenase activity was examined as described elsewhere (11).

**Analysis of the N-terminal amino acid sequence of outer membrane proteins in the 30-kDa range.** Proteins in the Sarkosyl-insoluble pellet prepared from 400 µg of purified *E. chaffeensis* were separated by a reversed-discontinuous (Rd) SDS-PAGE (2.5-cm-long 17% gel on top of 11-cm-long 12% gel) and electrophoretically transferred to a ProBlot™ membrane (Applied Biosystems, Foster City, CA) as described elsewhere (44). The portion of the membrane containing bound proteins was excised and analyzed with an Applied Biosystems protein sequencer (Model 470).

**Primer design for amplification of a *p28* gene encoding a 28-kDa major protein (P28) of *E. chaffeensis*.** The N-terminal amino acid sequence of P28 (one of the major proteins separated by RdSDS-PAGE as described above) was determined as D P A G S G I N G N F Y S G K Y M P. We designed a forward primer, FECH1, based on 6th to 12th amino acids of this sequence: 5'-CGGGATCCGAATTCGG(A/T/G/C)AT(A/T/C)AA(T/C)GG

(A/T/G/C)AA(T/C)TT(T/C)TA-3'. Amino acids at the 1 to 5 positions of the N terminus of P28 were not included in this primer design to increase annealing efficiency, since Ser with 6 codons was present at the 5 position. For insertion into an expression vector, a 14-bp sequence (underlined) was added at the 5' end of primer to create an *EcoRI* and a *BamHI* site.

A reverse primer was designed from two proteins which we found to be related to P28 based on N-terminal amino acid sequence comparison. One of the proteins was the *Cowdria ruminantium* major antigen protein (MAP)-1. The C-terminal sequence of the MAP-1 is (N terminus) . . . G G R F V F \* (C terminus) [\* : termination codon] (36). Another protein was the *Anaplasma marginale* major surface protein (MSP)-4 (24), of which the entire amino acid sequence is homologous to that of *C. ruminantium* MAP-1 (36). The C-terminal sequence of the MSP-4 is (N terminus) . . . G A R F L F S \* (C terminus). An oligonucleotide primer, RECH2, complementary to a DNA sequence corresponding to amino acid sequence conserved between the C termini of the MAP-1 and the MSP-4, (N terminus) G (G/A) R F (V/L) F \* (C terminus), was prepared with the addition of a 9-bp sequence (underlined) including a *NotI* site at the 5' end for ligation into an expression vector : 5'-AGCGGCCGCTTA(A/G)AA(T/C)A(C/G) (A/G)AA (C/T)CT T(C/G)C TCC -3'.

**Cloning, sequencing, and expression of the *p28* gene.** Genomic DNA of *E. chaffeensis* was isolated from purified organisms as described elsewhere (25). PCR amplification with FECH1 and RECH2 primers was performed using a Perkin-Elmer Cetus DNA Thermal Cycler (model 480). A 0.8-kb amplified product was cloned in the pCRII vector of a TA cloning kit, as described by the manufacturer (Invitrogen Co., San Diego, CA). The clone obtained was designated pCRIIp28. Both strands of the inserted DNA were sequenced by a dideoxy-termination method with an Applied Biosystems 373A DNA sequencer.

The 0.8-kb *p28* gene was excised from the clone pCRIIp28 by *EcoRI-NotI* double-digestion, ligated into *EcoRI-NotI* sites of a pET 29a expression vector, and amplified in *Escherichia coli* BL21(DE3)pLysS (Novagen, Inc., Madison, WI). The clone (designated

pET29p28) produced a fusion protein with a 35-amino acid sequence carried from the vector at the N terminus.

**Antisera and western blot analysis.** Convalescent-phase serum from a patient with clinical signs of human ehrlichiosis was used as described previously (31). For preparation of the rabbit anti-recombinant (r) P28 antibody, the gel band corresponding to the rP28 in SDS-PAGE was excised without staining, minced in phosphate-buffered saline (PBS), pH 7.4, and mixed with an equal volume of Freund's incomplete adjuvant (Sigma). The mixture (1 mg of protein each time) was subcutaneously injected into a rabbit every 2 weeks four times. Antibody titers of the patient serum and the rabbit anti-rP28 antibody were determined to be 1:2,560 and 1:1,280 against *E. chaffeensis* antigen by indirect immunofluorescence assay (IFA) as described elsewhere (30).

Western blot analyses were performed with 1:1,000 dilutions of these sera by a procedure described elsewhere (32). Alkaline phosphatase-conjugated affinity-purified anti-human, anti-rabbit or anti-mouse immunoglobulin G (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) were used at a 1:1,000 or 1:2,000 dilution as secondary antibodies.

**Immunoelectron microscopy.** *E. chaffeensis*-infected DH82 cells were sonicated and centrifuged at 400 x g for 10 min. The supernatant was then centrifuged at 10,000 x g for 10 min to obtain ehrlichia-enriched pellet. The pellet was resuspend and incubated with rabbit anti-rP28 antibody or normal rabbit serum (1:100 dilution) at 37°C for 1h in PBS containing 1 % bovine serum albumin (BSA-PBS). After washing, the ehrlichiae was incubated with gold-conjugated protein G (20 nm, Sigma) at 1:30 dilution for 1 h at room temperature in BSA-PBS. After washing again, the specimen was fixed with 1.25% formaldehyde, 2.5% glutaraldehyde, and 0.03% trinitrophenol in 0.1 M cacodylate buffer (pH 7.4) for 24h and postfixed in 1% osmium-1.5% potassium ferricyanide for 1 h (34). The section was then embedded in PolyBed 812 (Polysciences, Warrington, Pa). The specimen was ultrathin sectioned at 60 nm, stained with uranyl acetate and lead citrate, and observed with a Philips 300 transmission electron microscope at



60 kV.

**Southern blot analysis.** Genomic DNA extracted from the purified *E. chaffeensis* (200 ng each) was digested with restriction endonucleases, electrophoresed, and transferred to Hybond-N<sup>+</sup> nylon membrane (Amersham, Arlington Heights, IL), by a standard method (23). The 0.8-kb *p28* gene fragment from the clone pCRIIp28 was labeled with [ $\alpha$ -<sup>32</sup>P]dATP by the random primer method using a kit (Boehringer Mannheim, Indianapolis, IN) and the labeled fragment was used as a DNA probe. Hybridization was performed at 60°C in rapid hybridization buffer (Amersham) for 20 h. The nylon sheet was washed in 0.1 x SSC (1 x SSC containing 0.15M sodium chloride and 0.015M sodium citrate) with 1% SDS at 55°C and the hybridized probes were exposed to Hyperfilm (Amersham) at - 80°C.

**Cloning and sequencing of genomic copies of *E. chaffeensis p28* gene.** The *Eco*I and *Pst*I fragments of DNA, detected by genomic Southern blot analysis as described above, were inserted into pBluescript II KS (+) vectors, and the recombinant plasmids were introduced into *E. coli* DH5 $\alpha$ . Using the colony hybridization method (23) with the <sup>32</sup>P-labeled *p28* gene probe, four positive clones were isolated from the transformant. The positive clones were designated pEC2.6, pEC3.6, pPS2.6, and pPS3.6. These contained the ehrlichial DNA fragments of 2.6-kb (*Eco*R I), 3.6 kb (*Eco*R I), 2.6 kb (*Pst* I), and 3.6 kb (*Pst* I), respectively. The inserts of the clones pEC3.6 and pPS2.6 overlapped as shown in Fig. 5. The overlapping area was further confirmed by PCR of *E. chaffeensis* genomic DNA with two pairs of primer sets interposing the junctions of the four clones (Fig. 7). The 1.1- to 1.6-kb DNA fragments of *Hind*III-*Hind*III, *Hind*III-*Eco*RI, or *Xho*I-*Eco*RI in the pEC2.6 and pEC3.6 were subcloned for sequencing. DNA sequencing was performed with suitable synthetic primers by dideoxy-termination method as described above.

**Immunization of mice and *E. chaffeensis*-challenge.** The rP28 band in SDS-

PAGE was excised, minced, and mixed with an equal volume of Freund's incomplete or complete adjuvant. Nine BALB/c male mice (6 weeks old) were divided into two groups. Five mice were intraperitoneally immunized a total of four times at 10-day intervals; twice with a mixture of the minced gel with the rP28 (30 to 40 µg of protein per mouse each time) and incomplete adjuvant, and twice with a mixture of the recombinant protein (the same amount as before) and complete adjuvant. Four mice were intraperitoneally injected with a mixture of the minced gel without protein and the respective adjuvants. For ehrlichia-challenge, approximately  $1 \times 10^7$  DH82 cells heavily-infected with *E. chaffeensis* were disrupted by sonication in serum-free DMEM (GIBCO-BRL) and centrifuged at  $200 \times g$  for 5 min. The supernatant was diluted to a final volume of 5 ml, and 0.3 ml was inoculated intraperitoneally into each mouse 10 days after the last immunization.

**Detection of *E. chaffeensis* 16S rDNA in *Ehrlichia*-challenged mice.** At day 5 post-challenge, approximately 1 ml of blood was collected in an EDTA tube from each mouse. Total DNA was prepared from 0.2 ml of the buffy coat from the blood with a QIAamp blood kit (QIAGEN, Inc., Chatsworth, CA), and was used as the template for PCR detection of *E. chaffeensis* 16S rDNA. The PCR detection by primers HE1 (5'-CAATTGCITATAACCTTTTGGT TATAAAT-3') and HE3 (5'-TATAGGTACCGTCATTATCTTCCCTAT - 3'), which yield a 389-bp fragment specific to *E. chaffeensis* 16S rDNA (4), was performed as described previously (39). The procedure allows detection from  $\geq 10$  pg of genomic DNA from purified *E. chaffeensis*.

**Sequence analysis and GenBank accession number.** Nucleotide sequences were analyzed with the DNASIS program (Hitachi Software Engineering Co., Ltd., Yokohama, Japan). A homology search was carried out with databases of the GenBank, Swiss Plot, PDB and PIR by using the software basic local alignment search tool (2) in the BLAST network service (the National Center for Biotechnology Information, Bethesda, MD). Phylogenetic analysis was

performed by using the PHYLIP software package (version 3.5) [17]. An evolutionary distance matrix, generated by using the Kimura formula (17) in the PROTDIST, was used for construction of a phylogenetic tree by using the unweighted pair-group method analysis (UPGMA) [17]. The data were also examined using parsimony analysis (PROTPARS in PHYLIP). A bootstrap analysis was carried out to investigate the stability of randomly generated trees by using SEQBOOT and CONSENSE in the same package. The nucleotide sequence of the *p28* gene and its gene copies has been assigned GenBank accession numbers U72291 and AF021338, respectively.

## RESULTS

Identification of major outer membrane proteins of *E. chaffeensis*. The ehrlichial outer membrane fraction was prepared from Percoll-purified *E. chaffeensis* by Sarkosyl treatment. Transmission electron microscopy revealed that the purified ehrlichial fraction consists of a mixture of electron dense and light forms of *E. chaffeensis* with slight disintegration of inner membrane (Fig. 1A). Ehrlichiae were not surrounded with the host inclusion membrane. Various sizes of membrane vesicles ( $< 1 \mu\text{m}$ ) without significant ribosomes or nuclear materials were observed in the Sarkosyl-insoluble fraction from the organism (Fig. 1B). Succinic dehydrogenase (inner membrane marker enzyme of gram negative bacteria) activities were at less than the detection limit (1 n moles / min / mg of protein) in the Sarkosyl-insoluble fraction compared to approximately 10 n moles / min / mg of protein in the Percoll-purified organisms, suggesting that the insoluble fraction primarily consisted of the outer membrane of *E. chaffeensis*.

Analysis of the Sarkosyl-soluble and insoluble fraction of *E. chaffeensis* by SDS-PAGE suggested that proteins of 30-kDa range in the insoluble fraction represent the major outer membrane proteins of this organism (Fig. 2A). *E. canis* was antigenically cross reactive with *E. chaffeensis* (7, 31). A similar result was obtained in the case of *E. canis* using the same procedure with Sarkosyl (Fig. 2B). These findings indicate that the 30-kDa range proteins represent the major

60050353-091997

45

outer membrane proteins of these two *Ehrlichia* spp. Since it was impossible to resolve overlapping protein bands in the 30-kDa range of *E. chaffeensis* by conventional SDS-PAGE, RdSDS-PAGE was performed and at least five proteins of 30-kDa range in *E. chaffeensis* (P23, P25, P27, P28, and P29 designated from the molecular sizes in Fig. 2C) could be resolved from the Sarkosyl-insoluble proteins.

Cloning, Sequencing and expression of a *p28* gene encoding *E. chaffeensis* P28. A 0.8-kb *p28* gene, amplified by PCR, was cloned and sequenced as described in Materials and Methods (Fig. 3). The 0.8-kb DNA fragment, cloned in pCRII, had an open reading frame (ORF) of 756 bp encoding a 251-amino acid protein (including both PCR primer regions) with a molecular mass of 27,685 Da (Fig. 3). *E. coli* transformed with pET29p28 expressed a 31-kDa recombinant (r) P28 (Fig. 4A) which was larger than native P28 in size because of the fusion protein which a 35-amino acid sequence including the S.Tag peptide (20) derived from a pET expression vector was located at the N terminus. Serum from a patient with clinical signs of human ehrlichiosis reacted strongly to rP28 (31 kDa) in *E. coli*, P28 and P29 in *E. chaffeensis*, and also P30 in *E. canis* (Fig. 4B). The rabbit anti-rP28 antibody recognized not only rP28 (31 kDa) and P28, but also P29 and P25 of *E. chaffeensis* and P30 of *E. canis* (Fig. 4C), suggesting that P28 shares antigenic epitopes with P25 and P29 in *E. chaffeensis* and P30 of *E. canis*.

Immunoelectron microscopy. Transmission immunoelectron microscopy with colloidal gold-conjugated protein G and rabbit anti-rP28 antibody revealed gold particles bound to *E. chaffeensis* surface (Fig. 5). The distribution of the particles was random, close to the surface, and appeared as if almost embedded in the membrane, suggesting that the antigenic epitope protrudes very little from the lipid bilayer. Nonetheless, the antigenic epitope was surface-exposed, and thus, could be recognized by rabbit anti-rP28 antibody. No gold particles were observed on host cytoplasmic membrane or *E. chaffeensis* incubated with normal rabbit serum.

Identification and characterization of genomic copies of *E. chaffeensis p28*

gene. Genomic Southern blot analysis with several restriction enzymes resulted in one or more DNA fragment(s) of *E. chaffeensis* which could hybridize to <sup>32</sup>P-labeled *p28* gene probe (Fig. 6). The restriction enzymes used do not cut within the *p28* gene portion of the pCRII*p28* insert, and therefore, the Southern blot result shows that genes homologous to *p28* gene are present in the ehrlichial genome. *Xba* I, *Bgl* II, and *Kpn* I produced two bands, *Spe* I generated three bands, and *EcoR* V and *Pst* I produced multiple bands with different densities. *EcoR* I generated a broad band of 2.5 to 4 kb. These *p28* homologous genes are designated as *omp-1* (outer membrane protein-1) family.

Four DNA fragments from 2.6 to 3.6 kb were cloned from the *EcoRI*-digested and the *PstI*-digested genomic DNA of *E. chaffeensis* by colony hybridization with radiolabeled *p28* gene probe. The inserted DNA of the two recombinant clones, pEC3.6 and pPS2.6, were overlapped as shown in Fig. 7. Sequencing revealed one 5'-truncated ORF of 243 bp (designated *omp-1A*) and five complete ORF of 836-861 bp (designated *omp-1B* to *omp-1F*), which are tandemly-arrayed and are homologous to the *p28* gene (but are not identical), in the ehrlichial genomic DNA of 6,292 bp (Fig. 8). The intergenic spaces were 581 bp between *omp-1A* and *omp-1B* and 260-308 bp among others. Putative promoter regions and ribosome-binding sites were identified in the noncoding regions (Fig. 8).

Structure of proteins encoded in the genes of the *E. chaffeensis omp-1* family. Five complete *omp-1* gene copies (*omp-1B* to *omp-1F*) encode 279 to 287-amino acid proteins with molecular masses of 30,320 - 31,508 Da. *Omp-1A* encodes an 82-amino acid partial protein (9,243 Da) which lacks the N-terminal region (Fig. 6). The 25-amino acid sequence at the N-terminus of OMP-1B to OMP-1F (encoded in *omp-1B* to *omp-1F*) is predicted to be a signal peptide because three carboxyl-terminal amino acids of the signal peptides (Ser-X-Ala in OMP-1B, Leu-X-Ser for OMP-C, and Ser-X-Ser for OMP-1D and OMP-1F) are included in the preferred amino acid sequence of signal peptidase at the processing sites proposed by Oliver (27). The

putative cleavage site of the signal peptide is shown by vertical arrowhead in Fig. 8. The calculated molecular masses of the mature OMP-1B to OMP-1F from the predicted amino acid sequences are 28,181 Da for OMP-1B, 27,581 Da for OMP-1C, 28,747 Da for OMP-1D, 27,776 Da for OMP-1E, and 27,933 Da for OMP-1F. The estimated isoelectric points are 4.76-5.76 in the mature OMP-1B to OMP-1F. In Fig. 8, an underlined amino acid sequence in *omp-1F* gene (the 80th to 94th amino acids) was identical to the N-terminal amino acid sequences of *E. chaffeensis* native P23 protein as determined chemically, which indicates that P23 is derived from the *omp-1F* gene. Amino acid sequences identical to the N-terminal sequences of P25, P27, and P29 were not found in those from *omp-1* gene copies cloned in this study (data not shown).

Alignment of predicted amino acid sequences of the *E. chaffeensis* OMP-1s, including *Cowdria ruminantium* MAP-1 (36) which is related to the OMP-1 family, revealed substitutions or deletions of one or several contiguous amino acid residues throughout the molecules. The significant differences in sequences among the aligned proteins are seen in the regions indicated SV (semivariable region) and HV (hypervariable region) 1 to 3 in Fig. 9. Computer analysis for hydropathy revealed that protein molecules predicted from all *omp-1* gene copies contain alternative hydrophilic and hydrophobic motifs which are characteristic of transmembrane proteins. The HV1 and HV2 were found to locate in the hydrophilic regions (data not shown).

Similarities among amino acid sequences of the *E. chaffeensis* OMP-1s. The amino acid sequences of 5 mature proteins without signal peptides (OMP-1C to OMP-1F and a P28) were similar to one another (71-83%) but the sequence of OMP-1B was dissimilar to those of the 5 proteins (45-48%). The amino acid sequences of the 5 proteins showed an intermediate degree of similarity with that of *C. ruminantium* MAP-1 (59-63%), but the similarity between that of the OMP-1B and the *C. ruminantium* MAP-1 was low (45%). These relations are shown in a phylogenetic tree which was obtained based on the amino acid sequence alignment by UPGMA method in the PHYLIP software package (Fig. 10). Three proteins (P28, OMP-1D, and OMP-1F) and two proteins (OMP-1C and OMP-1E) formed two separate clusters. The OMP-1B was located

distantly from these two clusters. The *C. ruminantium* MAP-1 was positioned between the OMP-1B and other members in the OMP-1 family.

**Protection against *E. chaffeensis*-challenge in rP28-immunized mice.** To investigate whether immunization of rP28 induces protection against *E. chaffeensis* infection, 5 mice were immunized with rP28 and 4 mice were inoculated with acrylamide gel without the recombinant protein (control). Before challenge, all 5-immunized mice had a titer of 1:160 against *E. chaffeensis* antigen by IFA and all 4-nonimmunized mice were negative. Protection was assessed by PCR detection of *E. chaffeensis* 16S rDNA in the buffy coat of blood collected from the mice at 5 days postchallenge. *E. chaffeensis* can transiently establish infection in BALB/c mice. The infection is spontaneously cleared as *E. chaffeensis* cannot be reisolated in cell culture at day 10 postinfection (29). Day 5 is the optimum time at which establishment of ehrlichial infection can be examined by PCR without the influence of residual DNA from the ehrlichiae used as the challenge before the spontaneous clearance of organisms takes place. The *E. chaffeensis*-specific DNA fragment was observed in all nonimmunized mice but not in any immunized mice, indicating that immunization of rP28 apparently protects mice from ehrlichial infection (Fig. 11) and suggesting that the P28 is a potential protective antigen.

## DISCUSSION

The outer membrane is the site where the host and ehrlichial interaction takes place. So far, the outer membrane fraction has not been prepared from any *Ehrlichia* spp., consequently the protein composition of outer membrane has been unknown. Using a Sarkosyl method, we identified five major proteins (P23 to P29) in the insoluble fraction of *E. chaffeensis*. Three of the five (P25, P28, and P29) were found to be antigenically cross reactive using anti-rP28 antibody and the antigenic epitopes were surface-located in *E. chaffeensis* as demonstrated by transmission immunoelectron microscopy. These observations, in addition to results of analysis by transmission electron microscopy and examination of succinic dehydrogenase activity in the Sarkosyl-insoluble

BIOSCI-091997

fraction, support that the procedure using Sarkosyl is useful for preparation of a fraction enriched in outer membrane of *E. chaffeensis*. Just like *Orientia tsutsugamushi* (26), the concentration of Sarkosyl required for *E. chaffeensis* was lower than those required for other facultative intracellular bacteria (6, 18, 37).

This is the first report that the major outer membrane proteins of *E. chaffeensis* in 30-kDa range are identified and characterized at molecular genetic level and protein sequence level. We and other investigators previously reported protein antigens of *E. chaffeensis* ranging from 22 to 30 kDa in sizes (7-10, 13, 31, 40). The two dominant antigens, P28 and P29 in the current study, seem to correspond to two proteins of 28 kDa and 30 kDa by Rikihisa et al. (31), and 28 kDa and 29 kDa by Chen et al. (7), respectively. In both previous studies, the antigens were recognized predominantly by convalescent-phase sera from human ehrlichiosis patients. The P28 and P29 may also correspond to proteins of 29 kDa and 30 kDa by Chen et al. (8), respectively, both of which were recognized by 7C1-B and 3C7 monoclonal antibodies (MAbs). The current study using the anti-rP28 antibody and the report by Chen et al. [8] using the MAbs indicated that the P28 (the current study) and the 29 kDa protein (Chen et al. [8]) share antigenic epitopes with the P29 (the current study) and the 30 kDa protein (Chen et al. [8]), respectively. In the current study, the P25, P28, and P29 were recognized by anti-rP28 antibody.

*E. canis* 30-kDa protein was recognized by the antibody to rP28 of *E. chaffeensis* (the current study) and by the 7C1-B MAb to *E. chaffeensis* (Chen et al. [8, 10]). The 32-kDa MAP-1 of *C. ruminantium* (36) showed similarity with all members of the *E. chaffeensis* OMP-1 family in the amino acid sequences. The *C. ruminantium* MAP-1 also was cross reactive to a 27-kDa protein of *E. canis* (22),

By 16S rDNA sequence comparison, *E. chaffeensis*, *E. canis*, and *C. ruminantium* are closely related (12). Consequently, 30-kDa range proteins in the OMP-1 family may be common antigens among the three species in the tribe *Ehrlichieae*.



Using PCR-amplified *p28* gene as a probe, six similar genes were identified in *E. chaffeensis* genome. Genomic Southern blot result suggests the presence of additional *omp-1* gene copies. However, the precise number of the copies cannot be determined, since restriction site polymorphism in the gene copies may result in the production of several bands from a single copy.

Recently, in *Anaplasma marginale* which is related to *E. chaffeensis* by 16S rDNA sequence (12), two multigene families have been found (1, 28). In one of the families, multiple *msp-2* genes encoding a 36-kDa major surface protein constituted a minimum of 1% of the genome and were distributed widely throughout the chromosome. In addition, strain variations of the *msp-2* copies were demonstrated (28). In another family, *msp3* gene copies encoding a 63-kDa major surface protein also were distributed widely throughout the chromosome. The three unique *msp3* genes, *msp3-12*, *msp3-11*, and *msp3-19*, possessed a DNA sequence area homologous to that of *msp-2* within ORFs in the *msp3-12* and outside ORF in the *msp3-11* and *msp3-19* (1). It was found that the *omp-1* gene family of *E. chaffeensis* is different from those of *A. marginale*. First, the ORFs of *omp-1* gene copies are tandemly-arrayed in the genome. Second, amino acid sequences among the *omp-1* copies may have greater variation among those of *msp-2* copies of *Anaplasma*. The similarities were 45% to 83% among six *omp-1* copies whereas 95% between two *msp-2* copies identified (15). Strain variability similar to *A. marginale* may exist in *E. chaffeensis*, since strain variability of protein antigens with 7C1-B MAb has been reported by Chen et al. (8, 10).

In phylogenetic classification, three proteins (P28, OMP-1D, and OMP-1F) belong to the same cluster. The P23 (derived from *omp-1F* gene) which was identified in the *E. chaffeensis* outer membrane fraction also belongs to this cluster. It is unknown whether *omp-1D* and other gene copies in different clusters are silent genes. These genes at least are not actively expressed in *E. chaffeensis* cultured *in vitro*, since the products from the *omp-1* gene family except for P23, P25, P28, and P29, were not recognized in the Sarkosyl-insoluble outer membrane fraction.

We demonstrated that the rP28 protected mice from *E. chaffeensis* infection or accelerated

the spontaneous clearance of *E. chaffeensis*, suggesting that this or other *omp-1*-related proteins may be a protective antigen. Further molecular genetic studies are required for elucidating the mechanisms of the antigenic polymorphism or possible antigenic variation, i.e., whether selective expression of the *omp-1* gene copies are regulated at transcriptional level or by recombination events (gene conversions) among the unique gene repertoire, such as in the cases of the pili of *Neisseria gonorrhoeae* (19), *vmp* of *Borrelia hermsii* (5), and *vls* of *Borrelia burgdorferi* (43).

#### ACKNOWLEDGMENTS

This work was supported by grant RO1 AI33123 from National Institutes of Health. Dr. Norio Ohashi was a recipient of a 1995 postdoctoral fellowship from The Ohio State University and Dr. Ning Zhi was a recipient of a 1995 graduate student fellowship from The Ohio State University. We thank Dr. John Lowbridge for his assistance in N-terminal amino acid sequencing. Dr. Quin Lu for her assistance in DNA sequencing, Ms. Andrea Nicastro for her help in ehrlichial cultivation, and Dr. Jason Mott and Dr. Roy Barnewall for their editorial assistance.

#### REFERENCES

1. Alleman, A. R., G. H. Palmer, T. C. McGuire, T. F. McElwain, L. E. Perryman, and A. F. Barbet. 1997. *Anaplasma marginale* major surface protein 3 is encoded by a polymorphic, multigene family. *Infect. Immun.* 65:156-163.
2. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. *J. Mol. Biol.* 215: 403-410.
3. Anderson, B. E., J. E. Dawson, D. C. Jones, and K. E. Wilson. 1991. *Ehrlichia chaffeensis*, a new species associated with human ehrlichiosis. *J. Clin. Microbiol.* 29: 2838-2842.
4. Anderson, B. E., J. W. Sumner, J. E. Dawson, T. Tzianabos, C. R. Greene, J. G. Olson, D. B. Fishbein, M. Olsen-Rasmussen, B. P. Holloway, E. H. George, and A.

- 266160-556505
- F. Azad. 1992. Detection of the etiologic agent of human ehrlichiosis by polymerase chain reaction. *J. Clin. Microbiol.* 30:775-780.
5. Barbour, A. G. 1993. Linear DNA of *Borrelia* species and antigenic variation. *Trends Microbiol.* 1:236-239.
  6. Caldwell, H. D., J. Kromhout, and J. Schachter. 1981. Purification of Partial characterization of the major outer membrane protein *Chlamydia trachomatis*. *Infect. Immun.* 31:1161-1176.
  7. Chen, S.-M., J. S. Dumler, H.-M. Feng, and D. H. Walker. 1994. Identification of the antigenic constituents of *Ehrlichia chaffeensis*. *Am. J. Trop. Med. Hyg.* 50:52-58.
  8. Chen, S.-M., V. L. Popov, H. Feng, and D. H. Walker. 1996. Analysis and ultrastructural localization of *Ehrlichia chaffeensis* proteins with monoclonal antibodies. *Am. J. Trop. Med. Hyg.* 54:405-412.
  9. Chen, S.-M., V. L. Popov, E. L. Westerman, F. G. Hamilton, J. S. Dumler, H.-M. Feng, and D. H. Walker. 1996. Antigenic diversity among strains of *Ehrlichia chaffeensis*. p.329-334. In: J.Kasar and R. Toman, Eds. proceedings of the Vth International Symposium of Rickettsiae and Rickettsial Diseases. Stara Lesna, Sep. 1-6, 1996. Slovak Academy of Sciences, Bratislava, Slovak Republic.
  10. Chen, S.-M., X.-J. Yu, V. L. Popov, E. L. Weternan, F. G. Hamilton, and D. H. Walker. 1997. Genetic and antigenic diversity of *Ehrlichia chaffeensis*: comparative analysis of a novel human strain from Oklahoma and previously isolated strains. *J. Infect. Dis.* 175:856-863.
  11. Chopra, I., T. G. B. Howe, and P. R. Ball. 1977. Lysozyme-promoted association of protein I molecules in the outer membrane of *Escherichia coli*. *J. Bacteriol.* 132:411-418.
  12. Dame, J. B., S. M. Mahan, and C. A. Yowell. 1992. Phylogenetic relationship of *Cowdria ruminantium* agent of heartwater, to *Anaplasma marginale* and other

members of the order *Rickettsiales* determined on the basis of 16S rRNA.

Int. J. Syst. Bacteriol. 42:270-274.

13. Dumler, J. S., S-M. Chen, K. Asanovich, E. Triggiani, V. L. Popov, and D. H. Walker. 1995. Isolation and characterization of a new strain of *Ehrlichia chaffeensis* from a patient with nearly fatal monocytic ehrlichiosis. J. Clin. Microbiol. 33:1704-1711.
14. Dumler, J. S., J. E. Dawson, and D. H. Walker. 1993. Human ehrlichiosis: hematopathology and immunohistologic detection of *Ehrlichia chaffeensis*. Hum. Pathol. 24:391-396.
15. Eid, G., D. M. French, A. M. Lundgren, A. F. Barbet, T. F. McElwain, and G. H. Palmer. 1996. Expression of major surface protein 2 antigenic variants during acute *Anaplasma marginale* rickettsemia. Infect. Immun. 64:836-841.
16. Eng, T. R., J. R. Harkess, D. B. Fishbein, J. E. Dawson, C. N. Greene, M. A. Redus, and E. T. Satalowich. 1990. Epidemiologic, clinical, and laboratory findings of human ehrlichiosis in the United States, 1988. JAMA 264:2251-2258.
17. Felsenstein, J. 1989. PHYLIP-phylogeny inference package (version 3.3). Cladistics 5:164-166.
18. Filip, C., G. Fletcher, J. L. Wulff, and C. F. Earhart. 1973. Solubilization of the cytoplasmic Membrane of *Escherichia coli* by the ionic detergent sodium-lauryl sarcosinate. J. Bacteriol. 115:717-722.
19. Haas, R., and T. F. Meyer. 1986. The repertoire of silent pilus genes in *Neisseria gonorrhoeae*: evidence for gene conversion. Cell 44:107-115.
20. Kim, J. S. And R. T. Raines. 1993. Ribonuclease S-protein as a carrier in fusion proteins. Protein Science 2:348-356.
21. Maeda, K., N. Markowitz, R. C. Hawley, M. Ristic, D. Cox, and J. E. McDade. 1987. Human infection with *Ehrlichia canis*, a leukocytic rickettsia. N. Engl. J. Med.

316:853-856.

22. Mahan, S. M., N. Tebele, D. Mukwedey, S. Semu, C. B. Nyathi, L. A. Wassink, P. J. Kelly, T. Peter, and A. F. Barbet. 1993. An immunoblotting diagnostic assay for heartwater based on the immunodominant 32-kilodalton protein of *Cowdria ruminantium* detects false positive in field sera. *J. Clin. Microbiol.* 31:2729-2737.
23. Maniatis, T., J. Sambrook, and E. F. Fritsch. 1989. *Molecular Cloning: a Laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor N.Y.
24. Oberle, S. M., and A. F. Barbet. 1993. Derivation of the complete *msp-4* gene sequence of *Anaplasma marginale* without molecular cloning. *Gene* 136:291-294.
25. Ohashi, N., H. Nashimoto, H. Ikeda, and A. Tamura. 1992. Diversity of immunodominant 56-kDa type-specific antigen (TSA) of *Rickettsia tsutsugamushi*: Sequence and comparative analyses of the gene encoding TSA homologues from four antigenic variants. *J. Biol. Chem.* 267:12728-12735.
26. Ohashi, N., A. Tamura, M. Ohta, and K. Hayashi. 1989. Purification and partial characterization of a type-specific antigen of *Rickettsia tsutsugamushi*. *Infect. Immun.* 57:1427-1431.
27. Oliver, D. 1985. Protein secretion in *Escherichia coli*. *Annu. Rev. Microbiol.* 39:615-648.
28. Palmer, G. H., G. Eid, A. F. Barbet, T. C. McGuire, and T. F. McElwain. 1994. The immunoprotective *Anaplasma marginale* major surface protein 2 is encoded by a polymorphic multigene family. *Infect. Immun.* 62:3808-3816.
29. Perez, M., Y. Rikihisa, and B. Wen. 1996. Antigenic and genetic characterization of an *Ehrlichia canis*-like agent isolated from a human in Venezuela. *J. Clin. Microbiol.* 34:2133-2139.
30. Pretzman, C. I., Y. Rikihisa, D. Ralph, J. C. Gordon, and S. Bech-Nielsen. 1987. Enzyme-linked immunosorbent assay for Potomac horse fever disease. *J. Clin.*

- Microbiol. 25:31-36.
31. Rikihisa, Y., S. A. Ewing, and J. C. Fox. 1994. Western blot analysis of *Ehrlichia chaffeensis*, *E. canis* or *E. ewingii* infection of dogs and human. J. Clin. Microbiol. 32:2107-2112.
32. Rikihisa, Y., S. A. Ewing, J. C. Fox, A. G. Siregar, F. H. Pasariba, and M. B. Malole. 1992. Enzyme-linked immunosorbent assay and western immunoblot analysis of *E. canis* and canine granulocytic *Ehrlichia*. J. Clin. Microbiol. 30:143-148.
33. Rikihisa, Y., Y. Zhang, and J. Park. 1994. Inhibition of infection of macrophages with *Ehrlichia risticii* by cytochalasins, monodansylcadaverine and taxol. Infect. Immun. 62:5126-5132.
34. Su, H., N. G. Watkins, Y.-X. Zhang, and H. D. Caldwell. 1990. *Chlamydia trachomatis*-host cell interactions: role of the chlamydial major outer membrane protein as an adhesin. Infect. Immun. 58:1017-1025.
35. Sumner, J. W., K. G. Sims, D. C. Jones, and B. E. Anderson. 1993. *Ehrlichia chaffeensis* expresses an immunoreactive protein homologous to the *Escherichia coli* GroEL protein. Infect. Immun. 61:3536-3539.
36. van Vliet, A. H. M., F. Jongejan, M. van Kleef, and B. A. M. van der Zeijst. 1994. Molecular cloning, sequence analysis, and expression of the gene encoding the immunodominant 32-kilodalton protein of *Cowdria ruminantium*. Infect. Immun. 62:1451-1456.
37. Verstrete, D. R., M. T. Creasy, N. Caveney, C. L. Baldwin, M. W. Blab, and A. J. Winter. 1982. Outer membrane proteins of *Brucella abortus*: isolation and characterization. Infect. Immun. 35:979-989.
38. Weiss, E., J. C. Williams, G. A. Dasch, and Y.-H. Kang. 1989. Energy metabolism of monocytic *Ehrlichia*. Proc. Natl. Acad. Sci. 86:1674-1678.
39. Wen, B., Y. Rikihisa, P. A. Fuerst, and W. Chaichanasiriwithaya. 1995. Analysis of

266160-ES265009

- 16S rRNA genes of ehrlichial organisms isolated from horses with clinical signs of Potomac horse fever. *Int. J. Sys. Bacteriol.* 45:315-318.
40. Yu, X., P. Brouqui, J. S. Dumler, and D. Raoult. 1993. Detection of *Ehrlichia chaffeensis* in human tissue by using a species-specific monoclonal antibody. *J. Clin. Microbiol.* 31:3284-3288.
41. Yu, X.-J., P. Crocquet-Valdes, L.C. Cullman, J.F. Piesman, J.G. Olson, and D.H. Walker. 1996. Genetic divergence of a 120-kDa immunodominant protein of *Ehrlichia chaffeensis*: a potential recombinant diagnostic tool. p.324-328. In: J. Kasar and R. Toman, Eds. proceedings of the Vth International Symposium of Rickettsiae and Rickettsial Diseases. Stara Lesna, Sep. 1-6, 1996. Slovak Academy of Sciences, Bratislava, Slovak Republic.
42. Yu, X.-J., P. Crocquet-Valdes, and D.H. Walker. 1997. Cloning and sequencing of the gene for a 120-kDa immunodominant protein of *Ehrlichia chaffeensis*. *Gene*. 184:149-154.
43. Zhang, J.-R., J. M. Hardham, A. G. Barbour, and S. J. Norris. 1997. Antigenic variation in Lyme disease borreliae by promiscuous recombination of *vmp*-like sequence cassettes. *Cell* 89:275-285.
44. Zhang, Y., N. Ohashi, E. H. Lee, A. Tamura, and Y. Rikihisa. 1997. *Ehrlichia sennetsu* *groEL* operon and antigenic properties of the GroEL homolog. *FEMS Immunol. Med. Microbiol.* 18:39-46.

60059353-091997

## FIGURE LEGENDS

FIG. 1. Transmission electron microscopy of Percoll-purified *E. chaffeensis* (A) and the insoluble precipitate after 0.1% Sarkosyl treatment of the organism (B). Note outer membrane vesicles of various sizes in B. (Bar = 1  $\mu$ m).

FIG. 2. SDS-PAGE patterns of the insoluble precipitate and the soluble supernatant fraction after 0.1% Sarkosyl treatment of purified *E. chaffeensis* (A) and *E. canis* (B), and RdSDS-PAGE of major proteins in the 30-kDa range resolved from the Sarkosyl-insoluble pellet of *E. chaffeensis* (C). (A) Lanes: 1, Sarkosyl-soluble supernatant; 2, Sarkosyl-insoluble precipitate enriched with outer membrane; and 3, purified *E. chaffeensis*. (B) Lanes: 1, Sarkosyl-soluble supernatant; 2, Sarkosyl-insoluble precipitate; and 3, purified *E. canis*. Both gels were stained with Coomassie blue. Brackets indicate a 30-kDa cluster of major outer membrane proteins. (C) The separation gel used consisted of a 17% gel on top of a 12% gel. The Sarkosyl-insoluble precipitate prepared from purified *E. chaffeensis* was blotted on a ProBlot<sup>TM</sup> membrane and stained with amido black (lanes 1-6). The protein bands present in each lane of the membrane were excised, and the N-terminal amino acid sequence of each protein was analyzed. Numbers on right or left of panels indicate molecular mass in kDa.

FIG. 3. DNA sequence and translation of *E. chaffeensis* *p28* gene cloned in pCRIIp28. The N-terminal amino acid sequence of native P28 determined chemically is underlined. Five amino acid residues at the N terminus of P28 which were not included in the *p28* gene, are indicated by boldface. Arrows indicate annealing positions of the primer pair designed for PCR amplification of *p28* gene.

FIG. 4. Overexpression of *E. chaffeensis* *p28* gene (A), and western blot analysis with convalescent-phase serum from a human ehrlichiosis patient (B) and with a rabbit anti-recombinant (r) P28 antibody (C). (A) Lanes; M, molecular size markers; C, pET29a-transformed *E. coli* (negative control); R, pET29*p28*-transformed *E. coli*

60050353-041997



(recombinant), and the recombinant (rP28) protein indicated by the arrowhead. (B and C) Lanes; Eca, purified *E. canis*; R, pET29p28-transformed *E. coli*; and Ech, purified *E. chaffeensis*. A rabbit anti-rP28 antibody preabsorbed twice with pET29a-transformed *E. coli* at 37°C for 1 h each was used at a 1:300 dilution. Dominant protein antigens are schematically shown for designated molecular masses, P25 to P30, except for rP28 (31-kDa). Numbers indicate molecular mass in kDa.

FIG. 5. Transmission electron microscopy of *E. chaffeensis* immunogold-labeled with a rabbit anti-rP28 antibody. Protein G-gold particles (20 nm) are localized on the surface of the organism. (Bar = 0.1  $\mu$ m).

FIG. 6. Genomic Southern blot analysis of *E. chaffeensis* with a  $^{32}$ P-labeled 0.8-kb p28 gene probe of the PCRUp28 insert. Numbers indicate molecular size in kb.

FIG. 7. Restriction map of 6.3-kb genomic DNA including the *omp-1* gene copies in *E. chaffeensis*. The four DNA fragments were cloned from the genomic DNA (pPS2.6, pPS3.6, pEC2.6, and pEC3.6). A recombinant plasmid pPS2.6 has an overlapping sequence with that of pEC3.6. The closed boxes at the bottom show PCR-amplified fragments from the genomic DNA for confirmation of the overlapping area. Open boxes at the top indicate open reading frames (ORF) of *omp-1* gene copies with direction by arrows. Open boxes at the bottom show DNA fragments subcloned for DNA sequencing.

FIG. 8. DNA sequence of 6.3-kb genomic DNA of *E. chaffeensis* and the predicted amino acid sequences of *omp-1* gene copies. The sequence of putative ribosome-binding sites (RBS) and -10 and -35 promoter regions are underlined. The N-terminal amino acid sequence of *E. chaffeensis* P23 protein is underlined in the amino acid sequence of *omp-1F*. Vertical arrows show the putative cleavage site of the presumed signal peptide.

FIG. 9. Amino acid sequences alignment of seven *E. chaffeensis* OMP-1s and *Cowdria ruminantium* MAP-1. Aligned positions of identical amino acids with OMP-1F are

shown with dots. The sequence of *C. ruminantium* MAP-1 is from the report of Van Vliet et al. (36). Gaps indicated by dashes were introduced for optimal alignment of all proteins. Bars indicates semivariable region (SV) and three hypervariable regions (HV1, HV2, and HV3).


FIG. 10. Phylogenetic relationship among six members of the *E. chaffeensis* OMP-1 family and *Cowdria ruminantium* MAP-1. The evolutionary distance values were determined by the method of Kimura, and the tree was constructed by the UPGMA analysis. Scale bar = 5% divergence (in the amino acid sequences). The numbers at nodes are the proportions of 100 bootstrap resamplings that support the topology shown.

FIG. 11. PCR detection of *E. chaffeensis* 16S rDNA fragment from *Ehrlichia*-challenged mice which were previously immunized with rP28 or nonimmunized. Template DNAs were prepared from blood buffy coats (0.2 ml) of all challenged mice. Arrow shows the *E. chaffeensis*-specific 16S rDNA fragment (389 bp) obtained by PCR amplification. Lanes: 1, positive control (using a total DNA from DH82 cells infected with *E. chaffeensis* as template); 2, negative control (PCR reaction without template); 3-6, nonimmunized mice; 7-11, immunized mice; and 12, DNA 1-kb ladder marker (GIBCO).

60503153-091997

condition  
for  
reproduction


Fig. 1



25059553-09197  
25059553-09197

original

Fig. 2



62

60059353.091997

58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525  
 526  
 527  
 528  
 529  
 530  
 531  
 532  
 533  
 534  
 535  
 536  
 537  
 538  
 539  
 540  
 541  
 542  
 543  
 544  
 545  
 546  
 547  
 548  
 549  
 550  
 551  
 552  
 553  
 554  
 555  
 556  
 557  
 558  
 559  
 560  
 561  
 562  
 563  
 564  
 565  
 566  
 567  
 568  
 569  
 570  
 571  
 572  
 573  
 574  
 575  
 576  
 577  
 578  
 579  
 580  
 581  
 582  
 583  
 584  
 585  
 586  
 587  
 588  
 589  
 590  
 591  
 592  
 593  
 594  
 595  
 596  
 597  
 598  
 599  
 600  
 601  
 602  
 603  
 604  
 605  
 606  
 607  
 608  
 609  
 610  
 611  
 612  
 613  
 614  
 615  
 616  
 617  
 618  
 619  
 620  
 621  
 622  
 623  
 624  
 625  
 626  
 627  
 628  
 629  
 630  
 631  
 632  
 633  
 634  
 635  
 636  
 637  
 638  
 639  
 640  
 641  
 642  
 643  
 644  
 645  
 646  
 647  
 648  
 649  
 650  
 651  
 652  
 653  
 654  
 655  
 656  
 657  
 658  
 659  
 660  
 661  
 662  
 663  
 664  
 665  
 666  
 667  
 668  
 669  
 670  
 671  
 672  
 673  
 674  
 675  
 676  
 677  
 678  
 679  
 680  
 681  
 682  
 683  
 684  
 685  
 686  
 687  
 688  
 689  
 690  
 691  
 692  
 693  
 694  
 695  
 696  
 697  
 698  
 699  
 700  
 701  
 702  
 703  
 704  
 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712  
 713  
 714  
 715  
 716  
 717  
 718  
 719  
 720  
 721  
 722  
 723  
 724  
 725  
 726  
 727  
 728  
 729  
 730  
 731  
 732  
 733  
 734  
 735  
 736  
 737  
 738  
 739  
 740  
 741  
 742  
 743  
 744  
 745  
 746  
 747  
 748  
 749  
 750  
 751  
 752  
 753  
 754  
 755  
 756  
 757  
 758  
 759  
 760  
 761  
 762  
 763  
 764  
 765  
 766  
 767  
 768  
 769  
 770  
 771  
 772  
 773  
 774  
 775  
 776  
 777  
 778  
 779  
 780  
 781  
 782  
 783  
 784  
 785  
 786  
 787  
 788  
 789  
 790  
 791  
 792  
 793  
 794  
 795  
 796  
 797  
 798  
 799  
 800  
 801  
 802  
 803  
 804  
 805  
 806  
 807  
 808  
 809  
 810  
 811  
 812  
 813  
 814  
 815  
 816  
 817  
 818  
 819  
 820  
 821  
 822  
 823  
 824  
 825  
 826  
 827  
 828  
 829  
 830  
 831  
 832  
 833  
 834  
 835  
 836  
 837  
 838  
 839  
 840  
 841  
 842  
 843  
 844  
 845  
 846  
 847  
 848  
 849  
 850  
 851  
 852  
 853  
 854  
 855  
 856  
 857  
 858  
 859  
 860  
 861  
 862  
 863  
 864  
 865  
 866  
 867  
 868  
 869  
 870  
 871  
 872  
 873  
 874  
 875  
 876  
 877  
 878  
 879  
 880  
 881  
 882  
 883  
 884  
 885  
 886  
 887  
 888  
 889  
 890  
 891  
 892  
 893  
 894  
 895  
 896  
 897  
 898  
 899  
 900  
 901  
 902  
 903  
 904  
 905  
 906  
 907  
 908  
 909  
 910  
 911  
 912  
 913  
 914  
 915  
 916  
 917  
 918  
 919  
 920  
 921  
 922  
 923  
 924  
 925  
 926  
 927  
 928  
 929  
 930  
 931  
 932  
 933  
 934  
 935  
 936  
 937  
 938  
 939  
 940  
 941  
 942  
 943  
 944  
 945  
 946  
 947  
 948  
 949  
 950  
 951  
 952  
 953  
 954  
 955  
 956  
 957  
 958  
 959  
 960  
 961  
 962  
 963  
 964  
 965  
 966  
 967  
 968  
 969  
 970  
 971  
 972  
 973  
 974  
 975  
 976  
 977  
 978  
 979  
 980  
 981  
 982  
 983  
 984  
 985  
 986  
 987  
 988  
 989  
 990  
 991  
 992  
 993  
 994  
 995  
 996  
 997  
 998  
 999  
 1000  
 1001  
 1002  
 1003  
 1004  
 1005  
 1006  
 1007  
 1008  
 1009  
 1010  
 1011  
 1012  
 1013  
 1014  
 1015  
 1016  
 1017  
 1018  
 1019  
 1020  
 1021  
 1022  
 1023  
 1024  
 1025  
 1026  
 1027  
 1028  
 1029  
 1030  
 1031  
 1032  
 1033  
 1034  
 1035  
 1036  
 1037  
 1038  
 1039  
 1040  
 1041  
 1042  
 1043  
 1044  
 1045  
 1046  
 1047  
 1048  
 1049  
 1050  
 1051  
 1052  
 1053  
 1054  
 1055  
 1056  
 1057  
 1058  
 1059  
 1060  
 1061  
 1062  
 1063  
 1064  
 1065  
 1066  
 1067  
 1068  
 1069  
 1070  
 1071  
 1072  
 1073  
 1074  
 1075  
 1076  
 1077  
 1078  
 1079  
 1080  
 1081  
 1082  
 1083  
 1084  
 1085  
 1086  
 1087  
 1088  
 1089  
 1090  
 1091  
 1092  
 1093  
 1094  
 1095  
 1096  
 1097  
 1098  
 1099  
 1100  
 1101  
 1102  
 1103  
 1104  
 1105  
 1106  
 1107  
 1108  
 1109  
 1110  
 1111  
 1112  
 1113  
 1114  
 1115  
 1116  
 1117  
 1118  
 1119  
 1120  
 1121  
 1122  
 1123  
 1124  
 1125  
 1126  
 1127  
 1128  
 1129  
 1130  
 1131  
 1132  
 1133  
 1134  
 1135  
 1136  
 1137  
 1138  
 1139  
 1140  
 1141  
 1142  
 1143  
 1144  
 1145  
 1146  
 1147  
 1148  
 1149  
 1150  
 1151  
 1152  
 1153  
 1154  
 1155  
 1156  
 1157  
 1158  
 1159  
 1160  
 1161  
 1162  
 1163  
 1164  
 1165  
 1166  
 1167  
 1168  
 1169  
 1170  
 1171  
 1172  
 1173  
 1174  
 1175  
 1176  
 1177  
 1178  
 1179  
 1180  
 1181  
 1182  
 1183  
 1184  
 1185  
 1186  
 1187  
 1188  
 1189  
 1190  
 1191  
 1192  
 1193  
 1194  
 1195  
 1196  
 1197  
 1198  
 1199  
 1200  
 1201  
 1202  
 1203  
 1204  
 1205  
 1206  
 1207  
 1208  
 1209  
 1210  
 1211  
 1212  
 1213  
 1214  
 1215  
 1216  
 1217  
 1218  
 1219  
 1220  
 1221  
 1222  
 1223  
 1224  
 1225  
 1226  
 1227  
 1228  
 1229  
 1230  
 1231  
 1232  
 1233  
 1234  
 1235  
 1236  
 1237  
 1238  
 1239  
 1240  
 1241  
 1242  
 1243  
 1244  
 1245  
 1246  
 1247  
 1248  
 1249  
 1250  
 1251  
 1252  
 1253  
 1254  
 1255  
 1256  
 1257  
 1258  
 1259  
 1260  
 1261  
 1262  
 1263  
 1264  
 1265  
 1266  
 1267  
 1268  
 1269  
 1270  
 1271  
 1272  
 1273  
 1274  
 1275  
 1276  
 1277  
 1278  
 1279  
 1280  
 1281  
 1282  
 1283  
 1284  
 1285  
 1286  
 1287  
 1288  
 1289  
 1290  
 1291  
 1292  
 1293  
 1294  
 1295  
 1296  
 1297  
 1298  
 1299  
 1300  
 1301  
 1302  
 1303  
 1304  
 1305  
 1306  
 1307  
 1308  
 1309  
 1310  
 1311  
 1312  
 1313  
 1314  
 1315  
 1316  
 1317  
 1318  
 1319  
 1320  
 1321  
 1322  
 1323  
 1324  
 1325  
 1326  
 1327  
 1328  
 1329  
 1330  
 1331  
 1332  
 1333  
 1334  
 1335  
 1336  
 1337  
 1338  
 1339  
 1340  
 1341  
 1342  
 1343  
 1344  
 1345  
 1346  
 1347  
 1348  
 1349  
 1350  
 1351  
 1352  
 1353  
 1354  
 1355  
 1356  
 1357  
 1358  
 1359  
 1360  
 1361  
 1362  
 1363  
 1364  
 1365  
 1366  
 1367  
 1368  
 1369  
 1370  
 1371  
 1372  
 1373  
 1374  
 1375  
 1376  
 1377  
 1378  
 1379  
 1380  
 1381  
 1382  
 1383  
 1384  
 1385  
 1386  
 1387  
 1388  
 1389  
 1390  
 1391  
 1392  
 1393  
 1394  
 1395  
 1396  
 1397  
 1398  
 1399  
 1400  
 1401  
 1402  
 1403  
 1404  
 1405  
 1406  
 1407  
 1408  
 1409  
 1410  
 1411  
 1412  
 1413  
 1414  
 1415  
 1416  
 1417  
 1418  
 1419  
 1420  
 1421  
 1422  
 1423  
 1424  
 1425  
 1426  
 1427  
 1428  
 1429  
 1430  
 1431  
 1432  
 1433  
 1434  
 1435  
 1436  
 1437  
 1438  
 1439  
 1440  
 1441  
 1442  
 1443  
 1444  
 1445  
 1446  
 1447  
 1448  
 1449  
 1450  
 1451  
 1452  
 1453  
 1454  
 1455  
 1456  
 1457  
 1458  
 1459  
 1460  
 1461  
 1462  
 1463  
 1464  
 1465  
 1466  
 1467  
 1468  
 1469  
 1470  
 1471  
 1472  
 1473  
 1474  
 1475  
 1476  
 1477  
 1478  
 1479  
 1480  
 1481  
 1482  
 1483  
 1484  
 1485  
 1486  
 1487  
 1488  
 1489  
 1490  
 1491  
 1492  
 1493  
 1494  
 1495  
 1496  
 1497  
 1498  
 1499  
 1500  
 1501  
 1502  
 1503  
 1504  
 1505  
 1506  
 1507  
 1508  
 1509  
 1510  
 1511  
 1512  
 1513  
 1514  
 1515  
 1516  
 15

Fig. 4




Fig-5



60059353.091997

65

266T60-ESE6S09





Fig. 6



Fig. 2





466T60° ESE65009

Fig. 9

SV

HV1

ONP-1P	MICROPHIT TAVANSHAP GEFANOV DNG-CH---	PISENOV GEMOVAN NO-----	NOV OTTOVPOLO OMOSISAN GEMOVAN	30
ONP-1B	.....	.....	.....	31
ONP-1C	.....	.....	.....	32
ONP-1D	.....	.....	.....	33
ONP-1E	.....	.....	.....	34
ONP-1F	.....	.....	.....	35
ONP-1G	.....	.....	.....	36
ONP-1H	.....	.....	.....	37
ONP-1I	.....	.....	.....	38
ONP-1J	.....	.....	.....	39
ONP-1K	.....	.....	.....	40
ONP-1L	.....	.....	.....	41

HV2


ONP-1P	VEROVANIP LOPANOV MOBILEM SVETOVNO GEMOVAN	ETVALTE	NOGOSISAN GEMOVAN	184
ONP-1B	.....	.....	.....	185
ONP-1C	.....	.....	.....	186
ONP-1D	.....	.....	.....	187
ONP-1E	.....	.....	.....	188
ONP-1F	.....	.....	.....	189
ONP-1G	.....	.....	.....	190
ONP-1H	.....	.....	.....	191
ONP-1I	.....	.....	.....	192
ONP-1J	.....	.....	.....	193
ONP-1K	.....	.....	.....	194
ONP-1L	.....	.....	.....	195

HV3

ONP-1P	FEYICANOV TULANOV GEMOVAN GEMOVAN	VEROVANIP	VEROVANIP	280
ONP-1B	.....	.....	.....	281
ONP-1C	.....	.....	.....	282
ONP-1D	.....	.....	.....	283
ONP-1E	.....	.....	.....	284
ONP-1F	.....	.....	.....	285
ONP-1G	.....	.....	.....	286
ONP-1H	.....	.....	.....	287
ONP-1I	.....	.....	.....	288
ONP-1J	.....	.....	.....	289
ONP-1K	.....	.....	.....	290
ONP-1L	.....	.....	.....	291

69

Fig-10



60059353.091997

09/19/97 15:33 614 292 6473

OSU VET BIOSCI

036/036

60059353-091997




Fig. 11.

71

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**